A study on less explored plants with potential neuroprotective activity against neurodegenerative diseases

By

Abdullah Al Nayeem
ID: 16146017

A thesis submitted to the Department of pharmacy in partial fulfillment of the requirements for the degree of
Bachelor of Pharmacy (Hons.)

Department of Pharmacy
Brac University
December, 2020

Declaration

It is hereby declared that

1. The thesis submitted is my own original work while completing degree at Brac University.
2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
3. The thesis does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.
4. I have acknowledged all main sources of help.



ID: 16146017

Student Full Name
Student ID

Approval

The thesis titled “A study on less explored plants with potential neuroprotective activity against neurodegenerative diseases” submitted by

1. Abdullah Al Nayeem, ID:16146017

of Spring, 2016 has been accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelor of Pharmacy on 6th January, 2020.

Examining Committee:

Thesis Supervisor:

Md. Tanvir Kabir
Senior Lecturer
Department of Pharmacy, Brac University

Program Coordinator:

Dr. Hasina Yasmin
Professor
Department of Pharmacy, Brac University

Departmental Chairperson:

Prof. Dr. Eva Rahman Kabir
Chairperson
Department of Pharmacy, Brac University

Ethics Statement

This is to certify that this thesis titled “A study on less explored plants with potential neuroprotective activity against neurodegenerative diseases” is submitted for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (Hons.) from the Department of Pharmacy, Brac University constitutes my own work under supervision of Md. Tanvir Kabir, Senior Lecturer, Department of Pharmacy, Brac University and I have given appropriate credit where I have used language, ideas or writings of another.

Abstract

The gradual deterioration of the structure and function of neurons, including neural death, is known as neurodegeneration. The most known diseases of neurodegeneration are Alzheimer's, Parkinson's, Huntington's, Amyotrophic sclerosis lateral disease. These diseases are seen throughout the world including Bangladesh and for this reason the demand of neuroprotective agents are high. Now, there are some rare plants such as *Ginkgo biloba, Withania somnifera Magnolia officinalis* and *Hypericum calycimum L.* are used not only as folk medicine but also their extracts have shown some crucial effects in lab experiments. Some of the plants such as *Centella asiatica, Withania somnifera* and *Hypericum perforatum L.* decreases neural degeneration and also reverses amnesia. Here, this research is going to be discussing on the potential benefits of these plants as neuroprotective agents that are currently unclear or under research.

Keywords: Neurodegeneration, Amyloid-β, Senile plaque, Amyloid precursor protein, Superoxide dismutase 1.

Dedication

Dedicated to the Chairperson of Department of Pharmacy, Prof. Dr. Eva Rahman Kabir and my supervisor Md. Tanvir Kabir

Acknowledgement

All honors belong to almighty Allah for firmly strengthening me to complete my project work along with the courses needed to complete the Bachelor of Pharmacy (B. Pharm) program.

I am grateful to my respected supervisor, Md. Tanvir Kabir, Senior Lecturer, Department of Pharmacy, BRAC University, who was constantly helping me and encouraging me to finish the project article. It was almost impossible to finish my work on the project without his help.

I also appreciate the encouragement and opportunity provided to me by Prof. Dr. Eva Rahman Kabir, Honorable Chairperson, Department of Pharmacy, BRAC University, to complete my project work and B. Pharm program.

Table of Contents

List of Tables

List of Figures

List of Acronyms

ND	Neurodegenerative Disease
AD	Alzheimer's Disease
PD	Parkinson's Disease
HC	Huntington's Disease
SP	Senile Plaque
NFT	Neurofibrillary tangles
CSF	Cerebrospinal fluid
Aβ	Amyloid Beta
APP	Amyloid precursor protein
CAA	Cerebral amyloid angiopathy
AICD	Amyloid intracellular domain
MAP	Microtubule associated protein
PHF	Paired helical filament
MT	Microtubule
SOD 1	Superoxide dismutase 1
ALS	Amyotrophic lateral sclerosis
sAPPα	Soluble amyloid precursor protein α

Chapter 1 Background

ND can be a term for a number of diseases that affect the neurons of the human brain permanently. The overall malfunction of neuronal structure or the movement of neurons is neurodegeneration. As a result of neurodegenerative neurons, various neurodegenerative diseases such as amyotrophic, PD, AD, HC and prion disease occurs in humans. These diseases are severe and lead to slow degeneration in neurons and on neuron passage. As the study continues, some things tend to link these diseases on a subcellular basis to at least one other. Seeing these parallels creates promise for advances in treatment and may simultaneously mitigate many problems. There are various similarities between fully distinct neurodegenerative diseases and atypical protein classes as well as evoked cell death (Rubinsztein, 2006) (Bredesen, Rao, & Mehlen, 2006).

In several different stages of neurodegeneration, from the cellular to structural levels, neurodegeneration is also observed. While the clinical types of AD, PD and nerve cell disease vary, they have a range of characteristics: onset before or after lifespan, development as either a spontaneous or a legacy condition and hence the intra or extra-cellular accumulation and deposition of altered proteins. AD, PD and nerve cell diseases are among the largest prevalent and most problematic for civilization as a clump of degenerative brain disorders. In about 20 million people globally, are suffering for these three illnesses alone. Significantly, the AD, marked by a gradual neocortex dementia, can also have any of Parkinson's motor characteristics and pathological disorders. Even in the middle of progressive dementia, PD, mainly a motion and motor control condition affecting the afferent and efferent neuronal disorders. A disease that is expressed by muscle fatigue and waste of the motor neurons upper and lower within the neural system and brainstem. On the Island of Guam a PD complex syndrome has been observed for many decades consisting of overlaps of both PD and AD (Galasko, Salmon, Craig, Perl, & Schellenberg, 2002).

The similarities between mutated genes that disrupt the traditional manufacturing of related proteins with the subsequent aggregation in these conditions are identified by Taylor and colleagues (J. P. Taylor, Hardy, & Fischbeck, 2002). The main role of proteins to interrupt their regular processing in these diseases is still not identified properly, but the secret to designing rational therapeutic strategies is taken into consideration (Trojanowski & Lee, 2000). Over the last decade, epidemiological analysis into these degenerative brain disorders went from descriptive disease incidence tests to empirical risk factor studies. Genetic

epidemiology has been found to be effective in identifying the threats of gene variations, integrating knowledge in the genetics of conventional epidemiological approaches. Identifying further 'susceptibility genes' for these diseases would promote the study of risk factors in behavior and the environment. Epidemiology's ultimate purpose is to detect and eliminate illness (Mayeux, 2003). Moreover, there are some plants which have been used traditionally and some are showing promising results in lab experiments. For these reasons, these plants can also be taken into consideration.

Chapter 2 Neurodegeneration

Neurodegeneration is the fusion of two words which means neuro and nerve cell degeneration and progressive destruction. In certain disorders that lead to a loss of nerve structure and nerve activity, the term "neurodegeneration" is also used.

This decline eventually leads to a lack of cognitive skills such as memory and an improved cognitive process. The major focus so far is just one of three, including the Parkinson's disease, the HD and Alzheimer's, most importantly these are from ND. Neurodegeneration may be a central feature of many diseases that are coupled with the factor neurodegeneration. Important ignorance of an outsized proportion of less publicized diseases (M. Y. Davis, Keene, Jayadev, & Bird, 2014; Przedborski, Vila, & Jackson-Lewis, 2003). All this contributes to incremental brain injury and neurodegeneration. Each of the three diseases shows distinct clinical characteristics, cellular disease mechanisms look identical. For example, PD affects the brain's basal ganglia and dopamine depletes it. This ends with rigidness and trembling inside the body's main muscles, which are characteristics of the disorder. In AD, small protein plaques are accumulated, which weaken various areas of the brain and cause incremental memory loss. HC can be a chronic genetic disorder that affects the body's essential muscles, leading to extreme motor restraint and ultimately death. Genetic mutations have triggered only a particularly limited (less than 5 percent) proportion of neurodegenerative disorders. (Tsuji, 2010). The rest is assumed to be attributable to the following: the accumulation of toxic proteins in the brain, the loss of mitochondrial activity in which neurotoxic molecules are formed. However, the cause can differ. Now, experts typically accept that apoptosis and/or programmed necrobiosis is the result of intentional cell suicide to shield other nearby neurons against toxic substances potentially (Mandal, n.d.).

Chapter 3 Pathogenesis of neurodegeneration

3.1 Genetics

The bulk of genetic mutations in entirely not connected genes that cause a large number of neurodegenerative diseases. In a variety of different ND, the mutant gene got one thing in similarity and that is the triplet of glutamine amino acid repetition. The glutamine amino acid goes by the name CAG in the polyglutamine tract, which is known as poly Q. Repeated trinucleotides are known as diseases that are related to mutations of this type (Marsh, Lukacsovich, & Thompson, 2009) (Thompson, 2008).

The usual cause for predominant pathogenesis is polyglutamine repeats. Additional glutamine residue can acquire toxic effects, including unusual pathways to fold and degrade, altered sub-cell position, and abnormal interactions of the cell proteins (Marsh et al., 2009). A variety of animal models has been used for poly Q study for the well-defined cause that constantly expanding. A significant number of studies using nematode, fruit fly, mouse and non-human primates models were carried out (C. elegans) (Thompson, 2008) (Orr, 2009). The development of the CAG trinucleotide and polyQ tract, like HD, and even spinocerebel ataxias are responsible for nine heritable neurodegenerative disorders (Zoghbi & Orr, 2009).

3.2 Protein misfolding

Many NDs are classified as proteopathies, since the accumulation of deflated proteins is involved. Alpha-synuclein can generate insoluble fibroids such as PD, Lewy body dementia, multiple atrophy of the organ by Lewy pathologic disorders. Lewy's body fibrils are primarily structured by alpha-synuclein. In addition, the AD amyloid plaque, known as the non-A beta section contains alpha-synuclein fragment (NAC).

The central component of AD related to NFT’s is hyperphosphorylation of the tau protein.

Beta amyloid: the core segment of the AD plate.

Prion: Prion disease, the main component of which is spongiform encephalopathy.

3.3 Neurodegeneration created by intracellular mechanisms

3.3.1 Pathways to Protein Degradation

Intra-cellular toxic proteins are both PD and HD related, in the beginning of the aggregation. Proteinopsy diseases are known as protein aggregation diseases (Rubinsztein, 2006) and are caused in the following structures mostly by aggregates:

- Cytosol, for one. For example. Form 1 ataxia of spinocerebellar refill in endoplasmic (also seen leading neuroserpin inclusion bodies to family encephalopathy with mutations of neuroserpin)
- Residues extracellularly excreted, A-β in AD.

The degradation of distressed proteins or organelles by eukaryotic cells by two main mechanisms:

Ubiquitin protectasome is required to degrade several proteins, including polyQ and alpha-synuclein, in addition with enzymes, causing proteinopathy. The study of ubiquitin proteasomes found that the pathological proteins that could result in a toxic species could not be separated enough by proteasomal enzymes. This is the first cell route for the degradation of proteins (Rubinsztein, 2006).

The decreased activity of the proteasome is focused on models where the clusters of protein (intracellular) formats. It is not known to us that whether these clusters are or not a cause or consequences for neural degeneration (Rubinsztein, 2006).

Autophagic-lysosomal tracts: a programmed type of necrobiosis (PCD). This becomes the right direction for protein aggregation, and becomes proteasome substrate of a poor type. This is divided in autophagy of 2 classes:

- chaperone-mediated macroselfagy
- autophagy of CMA (Rubinsztein, 2006).

Macro autophagy requires macromolecular nutrient recycling under hunger, some apoptotic processes and if incomplete, the development of ubiquitous inclusions. Intraneuronal aggregates contribute to neurodegeneration in mice with neuronally-confined macro autophagic knockouts (Rubinsztein, 2006).

Neurodegeneration can result in chaperone-mediated autophagy defects. Research has shown that mutant protein binds on the lysosomal membrane to the CMA pathway receptors and thus also blocks its own degradation when other substrates are broken down (Rubinsztein, 2006).

3.3.2 Membrane damage

The disruption of monomeric or oligomeric proteins of the membranes of organelles can also lead to these diseases. Alpha-synuclein can cause induction of a membrane damage (Varkey et al., 2010) trigger large tubulation and vesiculation in artificial phospholipid vesicular incubation (Varkey et al., 2010). This lipid vesicles shaped tubes comprise both micellar and bilayer tubes. Extensive membrane curvature induction deletes the cell and ultimately causes necrobiosis (Mizuno et al., 2012). Alpha-synuclein may also form lipoprotein nanoparticles like apolipoproteins in addition to tubular structures (Varkey et al., 2013).

3.3.3 Defection in mitochondria

Intrinsic mitochondrial apoptotic pathways for neurodegeneration are the most critical form of necrobiosis. The activation of mitochondrial space in caspase 9 is controlled by this route by regulating cytochrome c discharge. Reactive species of oxygen are the usual byproducts of respiratory mitochondrial function (ROS). The ROS concentration mediates with antioxidants in mitochondria such as peroxidase and SOD. The formation of reactive oxygen species is an important aspect of a neurodegenerative disorder (oxidative stress). Moreover, mitochondria contain vital-sustaining roles such as balance of calcium, fission and fusion in mitochondria, lipid fusion in concentrated mitochondrial membrane and ROS generation in mitochondrial transmission of permeability. Mitochondrial disease which leads to neurodegeneration probably will at least at some point involve all these functions. (DiMauro & Schon, 2008).

In neurodegenerative pathogenesis of four most prominent disorders, mitochondrial dysfunction and oxidant stress, HD, PD, and ALS can provide a crucial role. (Lin & Beal, 2006). Neurons, due to their high mitochondrial activity, are highly vulnerable to oxidation due to their elevated transcription levels, high oxygen intake and poor protection against antioxidants (H. Wang et al., 2017) (Liu, Zhou, Ziegler, Dimitrion, & Zuo, 2017).

3.3.4 DNA damage

The brain is a fifth-scale metabolism for maximal oxygen intake and a significant cause of DNA damage in the brain is reactive oxygen generated by the metabolism of the oxidative.

Cell damage to DNA is extremely dangerous, because DNA cannot be substituted simply by re-synthesis in the template for protein processing, as opposed to other molecules. Post-mitotic neurons may become vulnerable to DNA degradation (such as oxidative lesions or other splitting in the DNA strand) but may also result in age accumulation of DNA damage and brain aging and neurodegeneration (Jeppesen, Bohr, & Stevnsner, 2011). DNA single-beam splits are frequently associated with ataxia-oculomotor apraxia neurodegenerative disorders (Liu et al., 2017) (Madabhushi, Pan, & Tsai, 2014). Increased oxidative DNA damage is attributed to Alzheimer and Parkinson's disease in the brain (Madabhushi et al., 2014). ND as example AD, amyotrophy, (A-T), disease named cockyne, xeroderma disease and PD have been linked to faulty DNA repair. (Jeppesen et al., 2011).

3.3.5 Axonal transport

In several different neurodegenerative disorders, axonal swelling and axonal spheroids are found. This suggests that damaged axons do not appear to be found only in diseased neurons but that by organelle aggregation, they inflict some pathological insult. Transportation by axon is often impaired by a variety of pathways that involve: kinesin and cytoplasmic dynein, microtubules, freight and mitochondria.(De Vos, Grierson, Ackerley, & Miller, 2008a). A degenerative pathway called Wallerian degeneration usually starts when Axonal Transport is severely disrupted (Coleman & Freeman, 2010).

3.4 Programmed necrobiosis

The intracellular program of necrobiosis programmed is death of the cell in all ways (Bredesen et al., 2006). In neurodegenerative disorders including PD, amyotrophic sculpture, Alzheimer's disease and Chorea of Huntington, this mechanism is often triggered. (Vila & Przedborski, 2003). PCD observers may also have clear pathogenicity in neurodegenerative diseases; PCDs may also appear as a reaction to other damage or disease processes (Engelberg-Kulka, Amitai, Kolodkin-Gal, & Hazan, 2006).

3.4.1 Apoptosis (type I)

In multicellular animals, an apoptosis may be a kind of programmed necrobiosis. It is one of the most common kinds of programmed necrobiosis (PCD) involving the production and death of characteristic cell morphology through a sequence of biochemical events.

Extrinsic apoptotic pathways: This is when outside-cell factors activate death receptors for cells surface (e.g. Fas) that end with caspase-8 or -10 activation (Engelberg-Kulka et al., 2006).

The product of mitochondrial release from cytochrome c or reticular endopathic defects, both of which contribute to caspase-9 activation. Golgi's heart and body were other organelles with weakened receptors that lead the cells into the abstract route. Intrinsic apoptotic pathways (Engelberg-Kulka et al., 2006) (Green & Kroemer, 2005).

Special amino acid residual cleaved caspases (cysteine-aspartic acid proteases). There are two types of caspases for the initiators and effectors. Inactive modes of caspas effector fall in Caspas initiators. This induces effectors dividing other protein that help to start the apoptotic (Engelberg-Kulka et al., 2006).

3.4.2 Autophagic (type II)

An organelle or misfolded protein can be ingesting aggressively by a cell, an autophagosome which is encapsulated. Now, a lysosome fuses with this encapsulation results in intracellular phagocytosis which results in the destructions of the autophagosome contents. Since certain ND require extraordinary clusters of protein, autophagic deficiencies might be the natural occurrence and are known to be neurodegenerative. (Engelberg-Kulka et al., 2006).

3.4.3 Cytoplasmic (type 3)

PCD also can occur through processes of necrobiosis of non-apoptotic, type III, or cytoplasm. As an example, PCD such as type three can be caused in receptor of trophic factor by hyperactivation or trophotoxicity. PCD-induced toxins in cytostome may cause low-level necrosis or higher aponecrosis. Autophagy may also be the form of intracellular phagocytosis in which cells ingest dangerous or misfolded organelles or proteins efficiently, embedded in a lysosome which merges into autophagosome material of a lysosome. What combinations of apoptosis, non-apoptosis and necrosis causing different forms of aponacrosis. Since certain neurodegenerative diseases require extraordinary protein aggregates, autophagic deficiencies may be a natural occurrence and are known to be neurodegenerative. (Engelberg-Kulka et al., 2006).

3.5 Transglutaminase effect in neurodegeneration

Human bodies enzymes known as transglutaminase are found in the whole body and surely inside the neural structure of brains (Caccamo, Currò, Condello, Ferlazzo, & Ientile, 2010).

Important features of the transglutaminases is the binding of peptides and proteins not only intermolecularly but also intramolecularly by transamination or cross-linking via a type of covalent bonds called isopeptide bonds (Caccamo et al., 2010).

This proteins and peptides are binding with Transglutaminase into a clump. The chemical and mechanical problems result in the structure resistants (Caccamo et al., 2010).

The most important human ND has the property of receiving irregular protein and peptide structures (Caccamo et al., 2010).

Per ND has one or more unique proteins or peptides for its own purposes. In AD, amyloid-beta and tau are present. The alpha-synuclein is found in PD. In HD, it's bumpy (Caccamo et al., 2010).

3.5.1 Transglutaminase substrates

The transglutaminase in vitro or in vivo are amyloid beta, tau, alpha synuclein, huntingtin and are thus expected to be related together and in theory, in the other brain transglutaminases (Caccamo et al., 2010).

3.5.2 Transglutaminase augmented expression

Transglutaminase enzyme expression has been shown to increase in certain neurodegenerative disorders (AD, HD and PD) (Caccamo et al., 2010).

Presence inside these systems of isopeptide bonding: the presence of irregular structures typical of these neurodegenerative diseases of the inside isopeptide bundles (results of transglutamina reaction) (Caccamo et al., 2010).

3.5.3 Co-localization

Co-location in the autopsy of patients with these diseases has been identified with the abnormal structures of transglutaminase caused by isopeptide (Caccamo et al., 2010). There is an enormous area of research to see AD pathogenesis and to prepare professional therapies. The promotion of neurodegenerative disease is a highly complex and dynamic disease. The cause of dementia is a big foreign one. Alone in us almost 5,3 million Americans are AD, of which 5,1 million are over 65 and 200 thousand younger in AD (Querfurth & Laferla, 2010). Extracellular Aβ plaque complete and intracellular neurofibrillary tangles (NFTs) conglomerations made from hyperphosphorylated microtubule-related ć are reported histopathological attributes of the AD. In basal, dormant, orbital neocortex, Aβ plaques first

develop and then ripen in the neocortex, the hippocampus, the amygdala, the diencephalon and basal ganglia. Aβ arises in the mesencephalon, the lower brain stem, and the brain cortex in basic conditions. This Aβ Convergence allows the cornering of the cereleum locus and the entorhinal and entorhinal brain regions (Querfurth & Laferla, 2010). It is seen in the specific stage as a major part of the disease movement in the hippocamps and neocortex.10 Aβ and NFTs and this audit focuses on the origin, pathogenies and components contributing to movement of AD.

3.6 Amyloid β and AD pathogenesis

Amyloid pathogenesis starts with modified cleavage by β secretases (BACE1) and α-secretases of the amyloid protein precursor (APP), essential protein in plasma film to develop insoluble Aβ fibrolets. Aβ then oligomerates, expands into synaptic keys and interferes with synaptic signaling (J. X. Chen & Yan, 2010). As a result, it polymerizes in complete plaques into insoluble amyloid fibrils. This polymerization induces kinases to occur that allow the tau protein associated with microtubules to become hyper-phosphorylated and to polymerase into insoluble NFTs. (Crews & Masliah, 2010). Microglia inscription containing plaques is used for the conglomeration of plaques and tangles. This encourages microglial efficiency and provocative response from the neighborhood and adds neurotoxicity.

Chapter 4 Neurodegenerative diseases

4.1 Alzheimer’s Disease

AD is one of the diseases, contributing to the degradation of the cortex's neurons and synapses and of some subcortical structures, triggering the temporal lobe, the parietal lobe and the singular cortical field cord atrophy (Wenk,2006). Pathology of AD is distinguished primarily by presence of senile plaques and neurofibrillary entices. The plates consist of 39-43 long amino acids (also called A-beta or Aßen) of small peptides. Beta-amyloid may be a fragment of a larger protein known as the amyloid precursor protein (APP), penetrating the neuron membrane. APP survival and post-injury recovery appears to play a role in normal neuronal development.(Priller et al., 2006) (Turner, O’Connor, Tate, & Abraham, 2003).



Figure 1: Comparison with good patients and the patient with Alzheimer's disease

APP is separated by enzymes, including gamma secretase and beta secretase, into smaller fragments. Beta-amyloid fibroids may be assembled in one fragment each to form thick extracellular plaques called senile or amylate plaques (Tiraboschi, Hansen, Thal, & Corey-Bloom, 2004) (Ohnishi & Takano, 2004).

4.1.1 Causes of AD

The anomalous production of proteins in and around mind cells is expected to induce AD. Amyloid, which retains structural pads around synapses, is one of the proteins included. Tau, whose structure is within the synapse, is called the other protein. Despite the fact that what makes this loop start is not entirely understood, researchers now understand that multiple signs have appeared for several years. As synapses are influenced, material mail (called synapses) that transmit messages or signals between synapses are additionally abated. Acetylcholine, the levels of one synapse, are extremely low in people with AD (Hölscher, 1998). Different parts of the brain recoil for a while. Recollections are responsible for the major regions usually affected. Different areas of the brain are affected by more irregular forms of Alzheimer's disease. The key symptoms may be vision or language disorders rather than memory.

4.1.2 Age

The most critical aspect is age. Every 5 years after 65 people are able to grow AD double. But the possibility of developing AD is not just for older people. There are nearly 1 in 20 people under 65. This is called early or early AD which can influence people around the age of 40 years.

4.1.3 Family ancestry

Genetics people from their previous generation may increase their risk of developing AD, despite the fact that there is no genuine increase in threat. In a few households, though, AD is triggered by a history of lonely traits and the risks of the disease are far greater. If few of the relatives of people have generated dementia over age and particularly at a young age, they will have to check for genetic guidance on data and advice about their chances of developing Alzheimer's disease in the most experienced.

4.1.4 Down's syndrome

The risk of AD is higher for individuals with Down syndrome.

This is because the hereditary failure underlying Down's syndrome will also contribute, for certain cases, to amyloid plaques piling up in the brain over time.

4.1.5 Head injuries

People with serious head trauma could be at increased risk of developing AD, but a lot of study in this field is still needed.

4.1.6 Cardiovascular disease

Research shows that multiple cardiovascular lifestyle conditions can increase the risk of AD. In other words:

- Smoking

There is solid proof that smoking can expand your danger of creating dementia. Not every person who smokes will get dementia, yet halting smoking is thought to decrease your danger down to the degree of non-smokers. A few purposes for this incorporate the way that the two most regular types of dementia, AD and vascular dementia, have both been connected to issues with the vascular framework (your heart and veins). It is realized that smoking expands the danger of vascular issues, including by means of strokes or littler seeps in the mind, which are likewise hazard factors for dementia (“Alzheimer’s disease - Causes - NHS,” n.d.).

Furthermore, poisons in tobacco smoke increment oxidative pressure and irritation, which have both been connected to creating of Alzheimer's ailment.

- Obesity

Obesity, or having overabundance muscle versus fat, is a realized danger factor for dementia. Yet, new examination demonstrates the danger level relies upon where the fat is put away on the body, and that it might be an ideal opportunity to trade out the scale for a measuring tape. Stoutness during middle age, by and large 40 to 60 years of age, has reliably been related with a higher danger of dementia sometime down the road. Nonetheless, reports of whether abundance fat is useful or hurtful for the intellectual capacity of grown-ups over age 65 have shifted. The clashing outcomes can be clarified by the manner in which heftiness has been estimated in earlier investigations, as indicated by new proof from an ongoing populace study inspecting the connection among stoutness and intellectual capacity in excess of 5000 individuals over age 60. This investigation proposes that dementia hazard is most connected with focal corpulence, or having overabundance tummy fat.

- Diabetes

Diabetes is viewed as a danger factor for vascular dementia. This sort of dementia happens because of cerebrum harm that is regularly brought about by diminished or obstructed blood stream to your mind. Numerous individuals with diabetes have cerebrum changes that are signs of both Alzheimer's malady and vascular dementia.

- Higher rate of blood pressure

Higher rate of blood pressure can destroy small vessels of blood in the brain that affect the mind and memory of the brain (Johns Hopkins Medicine, n.d.).

- High cholesterol

Neurology showed that individuals with elevated cholesterol concentrations had higher brain plaques than those with average or low cholesterol concentrations in an academic newspaper. Plaques in the brain are caused by protein amyloid aggregation. They are a classic symptom of AD.

4.1.7 Signs and symptoms of AD

The progression of the disorder is split into four phases with a history of rising cognitive and physical deficiency.

4.1.7.1 Pre dementia

Serious events are sometimes called moldy or upsetting. Detailed neuro-psychological assessments should be carried out eight years before anyone complies with the AD analysis criteria for minor psychiatric disease. These early incidents will influence the most unpredictable daily workouts. The big vulnerability in late learning realities, and impotence, are temporary developmental impairments that can hardly be confirmed. Failure to ask the main elements of concentration, form, alteration or dynamic cause or impedance may also be symbolic in the beginning of somaticized AD phases (memory of consequences and concept connections). There is a lack of care at this stage, which is the most relentless manifestation of neuropsychiatry throughout the course of the condition. Big manifestations, appeal and decreased experience are often common with unforeseen memory problems. In addition, the pre-clinical phase of the disease was dubbed mellow intellectual deficiency (MCI) (Grundman et al., 2004). The period of natural maturation and dementia is known also to be temporary. MCI may contain a range of symptoms and is often observed as an AD prodromal stage where the transcendent side effect is the cognitive decline.

4.1.7.2 Early

Persons of AD would inevitably be impeded by education and memory. Language deficiencies are infamous in a small number as retention problems; main skills, diagnostic or innovations implementation (apraxia). Promotion does not affect all memory thresholds equally. Recollection of the history of the person more formed (removes the memory), the experienced realities (semantic memory) and full memory (memory of a body that is better suited to doing things for example, with a bifurcation to eat and/or drink a glass) (Carlesimo & Oscar-Berman, 1992).

The majority of language difficulties are characterized by contract jargon and reduced comprehension of the word, leading to an overall decline in oral and compound language. In this point the person with Alzheimer's normally can provide simple thoughts adequately. (Carlesimo & Oscar-Berman, 1992). Whereas some production teamwork and the organization of problems (apraxia) can be possible when doing fine-engine errands such as composing, drawing or dressing, but they are often unnoticed. If the condition progresses, AD persons may often take-out multiple orders autonomously but may need assistance or supervision of the exercises that are most mentally challenging.

4.1.7.3 Moderate

Dynamic decay eventually hinders freedom and the participants are unable to perform any of the simple daily activities. Disk discourses get evident when jargon revision is powerless, resulting in frequent mistaken word substitutions (paraphasia) (Gold, Reis, Markiewicz, & Andres, 1995). Furthermore, ability to peruse and write is constantly lost. Complex engine arrangements are less coordinated and AD progresses, hence the risk of declining increases. Memory problems intensify during this period and the person can forget the perception of close relatives. The recollection of a long haul, which was previously unbroken, is obstructed.

The psychological and neuropsychiatric improvements are more general. Each day, weathering, crabbing and labile results, vomiting, unforeseen hostility upheavals, or care covering. There might be sunset as well. Around 30% of people with AD make illusionary mistakes and other hallucinating signals. Stuff often lose consciousness and disease cycle hurdles (anosognosia) (Grundman et al., 2004). Can cause urinary incontinence. This side effect can be minimized by transporting the client from the home to other long-haul care facilities, impacting families or carriers.

4.1.7.4 Advanced

The patient depends absolutely on guardians throughout the last stages. English is lowered to simple vocabulary or even words, which leads to the full lack of speech in the long term. Regardless of vocal language capacities, people will grasp and re-establish passionate signs on a daily basis. While intensity can still be present, exceptional lack of reaction and weariness are often more common manifestations. (Carlesimo & Oscar-Berman, 1992). After all, people with AD will not even be able to perform the less complex things autonomously; where they cannot and are unable, mass and portability degrade. Generally, the cause of death is not the virus, but an external component, such as weight ulcer or pneumonia (Swerdlow, 2007).

4.1.8 Effects of Alzheimer’s disease

AD is certainly not a treatable disorder which declines steadily over the long run. AD's drawn-out consequences can decimate mates, families and individuals alike. The performance results of AD include a component of:

- Self-destructive contemplations

- Failure to impart torment
- Failure to convey manifestations of sicknesses
- Trouble gulping
- Self-damaging conduct
- Expanded weakness to creating pneumonia and different diseases
- Wounds because of falling
- Helpless equilibrium
- Trouble controlling gut and bladder working
- A feeling of loss of self

4.2 (PD) Parkinsonism or Parkinson's Disease

In ND the Parkinsonism or Parkinson’s disease in also a very well-known disease (Elbaz, Carcaillon, Kab, & Moisan, 2015). Bradykinesias, rigidity, rest and stance flexibility are usually suggested. The crude prevalence of PD in Asian countries was estimated to range between 15 and 100,000 and 15 to 328 for 100,000 respectively. It was estimated that the PD was between 100,000 and 12,500 per 100,000. PD marks the death in the midbrain field of substantial nigra primarily of dopaminergic neurons. This limited necrobiosis is caused by unexplained disease. In specific, SNCA-ubiquitin creates complex compounds and also clusters are recorded in the Lewy that contaminates neuronal structure. Protein transport and regulatory defects, including RAB1, are considered to be critical in this mechanism of disease (HHMI.Org, n.d.). In addition, a handicap will contribute to aggregation in Lewy's bodies in the axonal transport of alpha synuclein. Experiments show the decrease in mutant alpha-synucleins in both wild and inherited Parkinson's disease with the use of cultivated neural axons. (De Vos et al., 2008a). Alpha-synuclein membrane damage may be another PD phase (Mizuno et al., 2012). Age is the most frequent factor in risk. Genes known as GBA, SNCA, MAPT and LRRC2 mutations may result in a genetic PD or increase a risk of PD. (A. A. Davis et al., 2016).

4.2.1 Signs and symptoms

Movement ("motor") are the most identifiable signs of PD (Jankovic, 2008). Non-psychiatric disorders (mood, perception, actions or altering thought) and sensory issues (particularly altered sense of smell) and sleep disturbances (non-motor symptoms like autonomic dysfunction), are normal. A number also arise at the time of diagnosis of non-motor symptoms (Jankovic, 2008).

4.2.2 Causes

Many risk factors are suggested, often in relation to the hypotheses of potential disease pathways (S. Y. Chen & Tsai, 2010). Increased risk of pesticide exposures and decreased risk in smoking are the main regularly repeated relationships (S. Y. Chen & Tsai, 2010) (Barreto, Iarkov, & Moran, 2015). Between PD and H, there is a potential relation. pylori infection that can hinder some medicines like levodopa from absorbing (Çamcı & Oğuz, 2016) (McGee, Lu, & Disbrow, 2018).

4.2.3 Environmental factors

Pesticides consumption and experience of headache is both connected to PD, although there are minor threats. The chance of developing a PD is minimal, but never cigarettes and never drank caffeinated drinks (Noyce et al., 2012). Low urate concentrations in the serum are associated with an elevated risk of PD (Chahine, Stern, & Chen-Plotkin, 2014).

4.2.4 Genetics

Analysis demonstrates that PD is a result of a dynamic genetic-environmental relationship (Kalia & Lang, 2015). Roughly 15% of those with PD have a family of the first grade of the disease, (Bilgiç, Hanağası, & Emre, 2010) and 5 to 10% of people with PD know that they have disease variants that are caused by mutations in one of many genes. (Lesage & Brice, 2009). Each of these gene mutations is not disease-causing. Substances of susceptibility contribute to high organism risk, sometimes alongside the red markers, also affect the age, stringency and development (Lesage & Brice, 2009). At least 17 autosomal dominant gene mutations, including SNCA, LRRK2/PARK8, GBA, PRKN, PINK1, DJ1/PARK7, VPS35, EIF4G1 and DNAJC13, CHCHD2 and UCHL1 may be involved in the development of PD (Kalia & Lang, 2015) (Dextera & Jenner, 2013).

About 5% of individuals with PD are mutated with GBA1 gene 1 (Stoker, Torsney, & Barker, 2018). In just 1% of the uninfluenced population, these mutations exist. If these mutations are present, the risk of developing PD is increased by 20‑30 folds. The PD for these mutants has the same clinical characteristics, but a preceding age and a quicker cognitive and engine loss. Glucocerebrosidase is encoded in this gene. This enzyme's low levels cause the disease of Gaucher.

SNCA gene mutations in PD are significant because alpha-synuclein is the protein that this gene encodes, the key constituent of this species (lewy) that accumulate in PD patients neuron (Lesage & Brice, 2009). ATM is activated by the Alpha synuclein, a repair kinase mostly responsible for the DNA injury, kinase signage (Abugable et al., 2019). Furthermore, the non-homologous end of DNA repair route is triggered by alpha-synuclein. The Lewy body becomes a connection in between decreased DNA repair and PD patient's brain neural cell necrosis for alpha synuclein aggregation (Abugable et al., 2019).

The mutations in genes that includes glucocerebrosidase, synuclein alpha, Leucine-rich repeat kinase 2, were identified as red mark for the sporadic in patients with Parkinson's (Lesage & Brice, 2009). Most common cause for spontaneous inherited PD in the LRRK2 gene is mutations, consisting of around 5 percent of disease history and three sporadic cases (Lesage & Brice, 2009) (Davie, 2008). The best hereditary chance for developing PD is a mutation in GBA (Kalia & Lang, 2015).

Multiple genes involved in the activity of lysosomes in Parkinson's, digest products such as cellular waste. Any cases of PD are also suspected of lysosomal dysfunction restricting cell resistance to disrupt alpha synuclein (Gan-Or, Dion, & Rouleau, 2015).

Mutations in the LRP10 gene were linked to an autosomal dominant variant (Quadri et al., 2018).

4.3 Huntington's disease

The huntingtin gene defects may be the unusual autosomal neurodegenerative disorder. Astrogliosis and medium spiny neurons are characterized by HD (Estrada Sánchez, Mejía-Toiber, & Massieu, 2008). Striatum is greatly affected by a predominant brain region, along with degeneration of front and tempo cortical components (Estrada Sánchez et al., 2008) . The striatal Relay Control subthalamic nuclei suggest that the balm pallidus is involved and activity-initiating. The poorer signal from subthalamic nuclei therefore minimize initiation

and regulation of movement, resulting in interference, in particular choreography (Crossman, 2000).

HD is caused by the expansion of the polyglutamine tract in the hunteringtin gene (mHtt). MHtt aggregates are also specifically toxic. They can also interrupt the molecular motor and the microtubules and inhibit the movement of major products like BDNF to interfere with regular axon transportation (De Vos, Grierson, Ackerley, & Miller, 2008b).

4.3.1 Signs and symptoms

HD symptoms most commonly arise between the ages of 30 and 50 years, but start at any age. (Huntington Disease, 2020). Its advance in the early, middle and late stages with an earlier prodromal stage are widely represented. Subtle changes in attitude, cognition disorders, physical capacities, irritability, and moods all remain unexplained in early stages (Caron, Wright, & Hayden, 1993). The physical signs are also the most common to observe (Stephanie, 2010). Nearly all with HD finally have similar physical symptoms; however, cognitive and behavioral symptoms start, improvement and range differ greatly between people (Jensen, Sørensen, Fenger, & Bolwig, 1993).

The physical signs are most typical of jerky, suspected and uncontrolled motion, known as chorea (Walker, 2007). Many citizens tend not to be aware or impeded by their unintended gestures (Dayalu & Albin, 2015). Chorea is often initially seen to be general restlessness, accidental little or uncompleted gestures, uncoordinated or slowed eye movements (Walker, 2007). These minor engine malformations usually occur at least three years prior to more apparent signs of motor dysfunction (Nguyen & Cenci, 2015). The simple signs like stiffness, wobbling or odd posture arise due to a development of the condition (Walker, 2007). There are indicators that the movement mechanism inside the brain is impaired (Montoya, Price, Menear, & Lepage, 2006). Functions of the psychomotor are degraded and any steps needed to control the muscles are impaired. Physical instability, abnormal face and problems with eating, swallowing and talking are typical outcomes (Walker, 2007). Sleep disturbances and weight loss are associated symptoms (Dickey & La Spada, 2018). Eating issues typically lead to weight loss and malnutrition (Aziz et al., 2008) (Vonsattel & DiFiglia, 1998). In general, juvenile HD develops quicker with a larger decrease in comprehension and choreoid is seen briefly, if ever in juvenile HD it is characteristic of Westphal for its variable slowness of motion, rigidity and trembling, including seizures. (Walker, 2007) (Dickey & La Spada, 2018).

Cognitive abilities are progressively impaired (Montoya et al., 2006). Executive roles, including planning, cognitive flexibility, abstract reasoning, acquiring rules, initiating correct steps and avoiding ineffective measures, are especially impaired (Montoya et al., 2006). Owing to the course of the condition, memory shortfalls tend to look. These limitations vary from brief memory shortcomings to long-lasting memory challenge, including episode deficits (life memory), procedural (corpuscule memory) and memorial management. (Montoya et al., 2006). In the long term, memory issues appear to escalate with dementia (Montoya et al., 2006).

Anxieties, depression, a decreased appearance of emotion, egocentrism, violence, and compulsion, later triggering or escalating addiction, including alcoholism, play and hypersexuality, are stated to be neuropsychiatric indications (Van Duijn, Kingma, & Van Der Mast, 2007). Difficulties were also found in the identification of other negative expressions (Montoya et al., 2006). The prevalence of the symptoms is very variable among studies, with approximate lifetime prevalence rates between 33% and 76%. (Van Duijn et al., 2007). These signs, frequently affecting the everyday functions and constituting a cause for institutionalization, are amongst the worse facets of illness for many patients and their families. (Van Duijn et al., 2007). The general population has more frequent suicidal thoughts and suicidal attempts than (Walker, 2007). People are also not conscious of Chorea, neurological impairments and mental difficulties. (Szyszkowicz, Kousha, Kingsbury, & Colman, 2016). Mutant huntingtin is expressed throughout the body and is linked to peripheral tissue anomalies which are caused specifically by such expression outside the brain. That involve atrophy of the muscles, heart insufficiency, poor glucose tolerances, weight loss, osteoporosis and atrophy of the testicles (van der Burg, Björkqvist, & Brundin, 2009).

4.4 (ALS) Lou Gehrig's Disease

Lou Gehrig's disease or Amyotrophic Lateral Sclerosis may be the degeneration problem targeted selectively by motor neurons. A subcomponent of family ALS patients revealed that in the 1993 gene encoding enzyme Cu/Zn SOD1, missense mutations were found. This discovery prompted researchers to identify mechanisms of SOD1-mediated illness. But the pathogens behind MTT SOD1 still need to be resolved. In certain cases, TDP-43 and FUS protein aggregates cause abnormalities more recently, and chromosome number nine is which is considered the most generally recognized cause for the intermittent Lou Gehrig’s disease.

Latest, independent in vitro studies show astrocytes in the first cell sites where SOD1 mutations act (Nagai et al., 2007) (Di Giorgio, Carrasco, Siao, Maniatis, & Eggan, 2007). Astrocytes inflict effects that are toxic for the neurons (motor). Study needed to be done to find the precise pathways about the toxic effect, but findings are significant when neurodegeneration requires the cells except neurons (Julien, 2007).

4.4.1 Signs and symptoms

Due to the degenerative effects of the upper and lower motor neurons, the disease causes muscle fatigue, atrophy and muscle spasm throughout the body. Persons with the disease can eventually lose the versatility to start and regulate all voluntary movement (Hobson & McDermott, 2016), Although the bladder and bowel work, the muscles (muscles responsible for the movement of the eye) are normally spared (Lui & Byl, 2009) until the ultimate stages of the disease (Brown & Al-Chalabi, 2017).

There are 30‑50 percent people with ALS who suffer cognitive or behavioral disturbance (Martin, Al Khleifat, & Al-Chalabi, 2017). Around half people with ALS undergo moderate cognition and behavioral changes, and 10-15% exhibit symptoms of frontotemporal dementia. (Hobson & McDermott, 2016). ALS behavioral characteristics are also recorded in repetitive phrases and movements, apathy, and lack of inhibition (Raaphorst, Beeldman, De Visser, De Haan, & Schmand, 2012). The most frequently recorded cognitive symptoms in ALS are language impairment, managerial dysfunction and social processing and verbal memory problems; there was no association between dysfunction and seriousness of disease meta-analysis (Beeldman et al., 2016). Cognitive and behavioral disorders, however, have been shown to associate with a decreased mortality in people with ALS and an increased caregiver burden. (Beeldman et al., 2016). Around half of the people with ALS are emotionally label of whom they yell or laugh for nothing; in those with bulbar-activity ALS it is more usual (Hobson & McDermott, 2016).

Samples of ALS pain include contractures (permanent shortened of muscular, joint and tendon), discomfort in spine, back pain in the shoulder and pressure ulcers, and can include pain with a number of ALS signs and neuropathic pain (nurturing from nerve damages), spasticity, physical clashes or nociceptive pain induced by decreased mobility and muscle weakness. (Chiò, Mora, & Lauria, 2017). In addition, sensory nerves and the autonomous nervous system are not impaired, meaning that the majority of people with ALS have a sense of sound, light, touch, smell and taste.

Chapter 5 Global impact of Neurodegeneration

During 2016, 276 million DALYs (Disability Adjusted Life Years), representing 11.6% of the worldwide Daly for all illnesses, is liable for the ND included in this study. Combined, 9 · 0 million deaths or 16.5% of global deaths in 2016 were the root cause of those diseases (V. L. Feigin et al., 2017). The online GBD results tool also provides frequency and prevalence figures for each neurological disorder. The described results and findings can also be interactively displayed using a platform for web data visualization. The largest community of global DALYs in 2016 included neurological disorders and cardiovascular diseases (excluding stroke). Combined NDs ranked second in terms of deaths following cardiovascular disease. Since 1990, neurological deaths have increased by 39% and DALYs have increased by 15%. Neurological disease. However, age normalized mortality rates drop by 28 percent over a corresponding timeframe suggesting that the demographic growth and aging rise contribute to higher world numbers while, as seen by lower age standardized rates, world population is vulnerable to a lower chance of death from these causes. Similarly, between 1990 and 2016, the age-standardized DALY rates declined by 27%. Tetanus, meningitis and encephalitis have been the few brain diseases that have reduced incidence and absolute deaths and DALYs.

Stroke contributed mainly to global dialysis related to the nerves in 2016, affecting 42.2% of DALYs. (Valery L. Feigin et al., 2019). It was followed by Alzheimer's and other dementia (10.5 percent) and meningitis, the second highest contributor (7.9 percent)(Valery L. Feigin et al., 2019). The age-standard DALY rates of stroke ranked first in 19 of 21 world regions of neurological disorders. Migraines ranked first in Australasia and Western Europe. The top four contributing neurological disorders were 21 GBD areas globally for immigration, AD and other dementias. Meningitis (second in Central, East and western Sub-Saharan Africa, 14th in Asia Pacific high income, second in southern Sub-Saharan Africa, and eighth in Central and Eastern Europe), and encephalitis have ranged significantly in the ranks of meningitis (second in central, eastern and western) (ranked fifth in south Asia and 14th in Australasia, western Europe, and high-income North America). Other high ranks include spinal cord injury (fourth in five areas with high revenues), TBI (fourth in Central and Eastern Europe) and tetanus (ranked sixth in eastern sub-Saharan Africa). The mixture of 15 types of neurological disorders examined indicate a slightly higher age standard DALY rates for males than for females (male-to-female ratio 1:12). In investigating individual diseases,

TBI, PD, tetanus, efferent neuronal conditions, and stroke with male-to-female ratios of at least 1,5 were found in males substantially higher burden (measured by age norm DALY rates) compared with females. In comparison, male-to-female percentages were just 0.7 for migraine, multisclerosis, and tension-specimen headache. The more prevalent causes of neurological DALYs for children under 5 years of age (i.e. tetanus, meningitis and encephalitis), especially for meningitis, were in both sexes (Valery L. Feigin et al., 2019). In people aged 5 to 29 years, DALYs from epilepsy were largest. In young and medium-aged adults, immigration and anxiety headache were significant contributors, and in females even higher than in males. Stroke burden grew quickly until around 80 years of age, and it was the main cause for neurological burden in males rather than females, between 60 and 84 years. Although the key factor behind the neurological strain was AD and other dementias from 90 years of age, the international number of dementia-related DALYs was between the ages of 80 and 89 years.

The habits of YLLs and YLDs by age are somewhat different due to neurological disorders. Infectious causes, stroke, AD and other dementia, brain and other CNS cancer and therefore the burden estimated for headaches, TbI and spinal cord damage are the main characteristic of Deaths and YLL, while YLDs was all the burden estimated for TBI and spinal cord lesion, since headaches were not known to be an intrinsic exploration of death. Other important causes to neurological conditions YLD were epilepsy, cavity and AD and other dementias.

The age-standardized DALYs in five countries with cumulative neurological disorders is over 7000 daily per 100 000 population in 2016: Afghanistan (9135 daily per 100 000 population); Kiribati (7477 daily disorders per 100 000 population); the Solomon Islands (6075 daily disorders per 100 000 population), the Central African Republic (7283 daily disorders per 100 000); and Somalia (7349 DALYs per 100 000) (Valery L. Feigin et al., 2019). All these countries have no general health data, and none have been included in the report for any neurological disorders. Estimates therefore primarily rely on predictive factors and geographical proximity and are therefore, very unsure. In Singapore, Peru, Ecuadorean, Costa Rican, Puerto Rical, Japan, Australia, Singapore, Switzerland, Canada and the Bermudas, 11 countries had DALY rates normal for age, but 2500 DALIs for 100 000 populations. In those countries the reasons for the low rates differed. For e.g., there is a low migraine rate in Taiwan and Japan, while the rate of stroke in Costa Rica was low. The five best neurological DALY countries were frequently struck at high rates of stroke; Somalia, the Central African Republic and Afghanistan also reported high meningitis and Somalia had tetanus levels

significantly higher than any of the four other countries. In 171 of 195 countries and regions, between 1990 and 2016 the age-standardized prevalence of neurologic DALYs declined significantly (Valery L. Feigin et al., 2019). There was no statistically meaningful improvement in 23 nations, and only in North Korea, the figure was 20 percent.

Only 3 out of 15 types of neurological disorders accounted for 10% of DALYs attributable to 84 risks quantified in GBD 2016. Risk-associated DALYs make up 88.8% of all DALY-strain, 22.3% of the DALY-strain, and 14.1% of idiopathic DALY-strain. The proportion of risk attributed DALYs (meningitis, encephalitis, and multiple sclerosis) for the opposite neurological conditions were either very minimal or nil (tetanus, brain and other CNS cancer, migraine and tension-type headache, PD, and efferent neuron diseases). The estimated number of people living with dementia in 2015 was expected to be 46.8 million and is expected to hit up to 50 million in 2017 (Allied Academies, 2020). This are almost twice as high, exceeding 75 million every 2030 and 131.5 million every 2050 (Allied Academies, 2020). Much can be achieved with the development of countries. Of those with dementia, 58% live in low- and central-paid countries, but this will be 68% by 2050 (WHO, 2013). China, India and their South Asian and Western Pacific neighbors are the fastest growing population in the old population (Mcgill-carter, 2020).

The maturation of the division is a complete loop, reflecting the victories of better healthcare in the last century. Most have longer and more profitable lives, so the overall population has a more influential extent of developed citizens. Dementia is largely caused by more mature people, while cases starting before 65 years of age have become particularly important.

Any year in the world, over 9.9 million new dementia cases are present, leaving a new occurrence every 3.2 seconds (prince, 2015). ADI's global estimates of the prevalence, incidence and costs of dementia are revised with the World Alzheimer Report2015 based on effective surveys. The study provides valuable recommendations for a global dementia scheme. The research also contains a study for and against late disease trends and dementia rates, as well as a review of the broader cultural impact of dementia after a while.

Almost 50 million people globally suffer Alzheimer's or associated dementia (Monti et al., 2020). Alzheimer's and dementia in Western Europe are most common (Blum et al., 2018). In Sub-Saharan Africa, Alzheimer's is least frequent. The primary cause of issues in the latter stage of life is Alzheimer's and other demenzas. In low and middle-income countries 68% of

the predicted rise in global prevalence and dementia pressure by 2050 will be in (prince, 2015) (Stern et al., 1994).

In 2015, global dementia expenses were projected to be 818 billion dollars (US a rise of 35% relative to 2010; 86% in high-income countries. Informal treatment costs and therefore, direct social care costs also amount to the same percentage of overall costs, whereas medical costs are significantly smaller. The edge people would be crossed by $1 trillion in 2018 (Wimo et al., 2017).

Direct clinical costs typically account for 20% of worldwide costs of dementia, while direct social and informal costs generally equate to 40% for each record. In the African Districts and least in North America, Western Europe and some South American districts the general presence of casual factors is most significant, although otherwise the costs of the social segment are applicable.

Chapter 6 Impact of neurodegeneration in Bangladesh

A partnership research by the World Health Organization (WHO the Planet bank and the Harvard School of Public Health (GBD) has drawn the world's attention to the burden of neurological ailments and many other chronic disorders. The GBD study has been carried out in a joint venture. Traditional epidemiological and health statistical methods which take only mortalities but not disability rates into account significantly undervalued the burden of neurological disorders (Valery L. Feigin et al., 2019). The GBD research has demonstrated that the public health consequences of neurological diseases have been exaggerated over the years (Alam, 2017). Fifty million individuals had seizures in the World Health Organization (WHO). The number of people with dementia is predicted to double every 20 years. The global prevalence of disease is over 6 per cent of neurological diseases and some of the reverse conditions with neurological disorders and sequelae, and in many low- and middle-income countries this burden is especially high. The trend of hospital neurological admissions in the various areas of the world differs according to several reasons, including geographic neurological diseases (Moritz, Fox, Luscombe, & Kraemer, 1997). Philip-Ephraim estimated that 24.2% of all medical disorders in a single-year cycle are neurological illnesses, and the most frequent explanation of admissions was 42.1, accompanied by peripheral neuropathy (13.8%) and meningoencephalitis (7.2 percent) (Alam, 2017). So, it's very clear that the leading cause for neurological admissions and death remains stroke. Eze and Kalu recorded that 62% of neurological admissions were stroke. Others involved central nervous system

infections (CNS) and decreasing neurodegeneration conditions, epilepsy disorders, hypertension encephalopathies, and myelopathies. CNS tumors. The most common neurological conditions were identified with stroke and CNS infections. In a study other than this the specter of neurologic disorders is 64.9%, central nervous system infections (21.8%, HIV related nervous system infections (3.5%). Hypertensive neurologic conditions (3.4%), DA (3%), sub-arachnoid hemorrhage (2.2%), Guillain Bar, also found that neurological admissions account for approximately 14.8% of medical admissions. Overall, 78.2 percent of neurological admissions represented a non-infectious disorder while 11.8 percent represented infectious diseases (Alam, 2017). There is a good variety of psychiatric disorders. The high frequency of CNS infections means that prevention action should be taken. The shortage of specialist resources is a critical problem to overcome in the treatment of neurological disorders. In the 1960s in Bangladesh, neurology was introduced as a discipline. The next risk of death and morbidity in Bangladesh is the excess incidence of cerebrovascular disorder and stroke. Neurological conditions are very prevalent in all hospital admissions, and there's an inadequacy elsewhere so tertiary neurological referral institute called National Institute of Neuroscience and Hospital is referred to as any neurological problems (NINS&H) (Alam, 2017). Although the number of neurologists in Bangladesh has risen in the last decade, it is still inadequate. Internists are also treated by certain people with neurological disorders (Forbes, Craig, Callender, & Patterson, 2004). From different specialties. from different specialties. Studies have proven the usefulness of neurology liaison in particular in hospitals with tertiary services such as NINS&H, and medical care has increased in the area of specialist care. CNS and stroke infections are both precautionary. The major burden of nervous disease and a focus on preventive medicine should be protected by health planning.

A two or more information’s are accessible about the quantity of AD persistent in Bangladesh. There is no exact epidemiological information of AD in this nation. Here, the mindfulness about AD is presently in essential stage. Along these lines, influenced quiet and their relatives are confronting various issues persistently. The reserve for leading exploration on AD is restricted. A lower center salary nation like Bangladesh isn't yet ready for the administration of AD. At present, the vast majority of the individuals of the nation are in the youthful gathering. Be that as it may, inside 20–30 years there will be gigantic senior gathering individuals in this nation (Rahman, Tajmim, Ali, & Sharif, 2017).

Accordingly, there will be more odds of events of ND. Thus, the opportunity has already come and gone to consider the sickness and its administration as a proactive way and make

essential move in such manner. The strategy creators, well-being proficient and united gatherings should approach to make public need for ND in Bangladesh.

Chapter 7 Hypothesis related to neurodegeneration

7.1 The amyloid cascade hypothesis

AD, which is portrayed by dynamic disintegration in insight, capacity, and conduct, puts an extensive weight on western social orders. It is the 6th driving reason for all passing and the fifth driving reason for death in people matured ≥65 years. Until this point in time, an expected 5.4 million Americans have AD, yet because of the time of increased birth rates age, the frequency in 2050 is relied upon to contact a million people for each year, bringing about an all-out assessed predominance of 11 to 16 million influenced people (Shampo, Kyle, & Steensma, 2013).

Since the main portrait of Alois Alzheimer's presenile dementia in 1907, the main obsessive symptoms of AR have been senile plates (SP) and neurofibrillary tangles (NFTs). The proposal to establish the 'Amyloid Cascade Theory' has been drawn up by distinguishing evidence of β-amyloid (Aβ) in SPs or by legacy investigations detecting shifts in Amyloid Precedent Proteins (APP), presenilin 1 (PSEN1) and involvement 2 (PSES2). According to ACH, Aβ is the essential neurotic cause in the disorder, and thus contributes to the development of NFTs, neuronal cell transmission and dementia. While the hypothesis incorporates amazing facts, there seem to be contradictory beliefs. This paper summarizes the existing facts for and against the course of amyloid in AD.



Figure 2: Amyloid cascade hypothesis, (Reitz, 2012)

As portrayed over, two key perceptions brought about the first definition of the ACH. To begin with, the recognition of Aβ as a primary constituent of the SPs and second transformations of the APP, PSEN1, and PSEN2 qualities, which were found in families with beginning stage AD (FAD, malady beginning < 60 years). As a result of these perceptions, the presence of Aβ inside SPs was deciphered as an impact of these transformations that accordingly prompts cell demise and dementia. Since FAD has—aside from the previous beginning—a comparable phenotype to late-beginning AD, it was expected that this amyloid statement could clarify the pathogenesis of a wide range of AD (Levy-lahad et al., 1995).

7.2 The Mitochondrial Cascade Hypothesis

It comprises of three fundamental parts.

First the mitochondrial speculation retains the heritage of quality which characterizes the mitochondrial work of an individual. In this respect, both mothers and fathers have contributed to the AD threat of their posterity, but with mitochondrial DNA (mt DNA) mothers who have been purchased maternally deliver more.

Second, acquired and ecological elements decide the rate at which age-related mitochondrial changes create and show. On the off chance that, as information propose, declining mitochondrial capacity or productivity drives maturing phenotype, at that point more

prominent mitochondrial strength should connect with slower cerebrum maturing and lesser mitochondrial solidness should connect with quicker mind maturing.

This hypothesis maintains that persons start with a certain degree of mitochondrial function and that the mitochondrial function of each organism decreases at a certain rate. Eventually, the mitochondrial reduction reaches a threshold and induces AD-related histology changes. The question mark suggests improvements in the mitochondrial structure of APP, SAPP α or A β . In FAD, if changes in FAD like APP, sAPPα or Aβ homeostasis cause dysfunction with Mitochondria, these changes could end in LOAD active pathways.

Third, the mitochondrial and utilitarian exchange rate calculation of an individual affects its AD spectrum. People with low expectations and fast rate of mitochondrial declines can produce signs and improvements in the AD histology at younger ages relative to those with high-scale mitochondrial decline and mild paces. Those with fewer exceptional mixtures, such as low measurements and mild mitochondrial declines or high trends or fast with gestion, can cause side effects and modifications of the AD histology in the middle ages (Trifunovic et al., 2004) (Kujoth, Leeuwenburgh, & Prolla, 2006) (Ross et al., 2013).

7.3 Senile plaque

Many biofilm items dependent on pathogen form and compounds could be contained inside the biofilm. In this respect, microorganisms in biofilms have shown increased tolerance to anxiety and anti-infection agents, even when they are unsensitive interventions, which offer the current framework an ideal specialty for ensuring microorganism treatment in nature and above all, for the host (Tshikantwa, Ullah, He, & Yang, 2018). Although the SPs present in the CNS are also responsible for the presence of a number of infectious agents as an anti-A β operation in bacteria, while brooding around this disease speculation (polymicrobial).

The plaques carry HSV-1 DNA, so senile plaques (biofilms) are commonly known to contain multiple nucleic acids (Natrajan et al., 2008). Knowing SP's structural behavior is important. In SP, spiral waves, literally microbes' amyloids, which in addition to pick cross seed atoms for propagation also achieve amylium-β like compliance (J. D. Taylor & Matthews, 2015). In a wide variety of micro-orgasmic sections, there was definitely also considered SP filament as the most important factor for practical external cellular structures for environmentally and infectious bio-protection agents. In this way, A β in the brain that ultimately can generate SPs can be hypothesized for certain microbial elements that set out the basic framework of

the bio-protection layer (Hermans, 2015) (Torrent, Pulido, Victò Ria Nogué, Boix, & Seifert, 2012). PSEN1 is encoded for PSEN1 as represented by the focal authoritative opinion, one of four notable proteins found in the presenilin complex. This PSEN1 protein is then used to regulate the APP scale in the brain. Overproduction of the APP leads to neurofibrillary tangles and amyloid plaques present in those with AD, as shown below: senile plaques delivered causing neuronal cell decay, decline and efficacy frequently. This data reveals, together how AD is multifaceted, which means that the disease phenotype chain response starts with PSEN1, a protein that matches with APP and Gamma secretase rules. ("Presenilin I Protein - AD: the influence of presenilin I," n.d.).

7.4 Hyper phosphorylation of Tau

Additionally, the existence of NFTs explains AD promotion. This nodes are the effects of microtubule-related β protein hyperphosphorylation (Eftekharzadeh et al., 2018). In the phone cytoplasm of neurons, and furthermore in their cycles, NFTs are pieces of combined and helically twisted protein fibers. The protein has a room to microtube and co-assemblies with a formed tubulin to microtubules that remain stable (Claeysen et al., 2012).



Figure 3: Hyper phosphorylation of Tau (Johnson & Stoothoff, 2004).

It has the power to settle and interrelate micro-tubules between bordering micro-tubules, to frame and keep up the legally stable organization of micro-tubules. The fullness of A β in the earth contributes to hyperphosphorylated as the protein comes into contact with provided kinases. Its hyper-phosphorylation contributes to oligomerization. During the breaking up of tubular sub-units, the tubes become shaky and then become gigantic tau fibers, completely NFTs. Tubes become shaky. These NFTs are straight patches in the neuronal cytoplast and cycles, resulting in an odd lack of correspondence between the neurons and the sign that eventually prepares apoptosis in the neurons. (Council, Road, & Kingdom, 2001). It has been accounted for that solvent Aβ controls cleavage and phosphorylation of τ for NFT age.

In addition, certain kinases such as glycogen Synthase kinase 3 (GSK3β) and cyclic-subordinate kinase 5 (CDK 5), which is operated by extracellular Aβ, direct phosphorylation of Ś. Although GSK3β and CDK5 are mainly reliable kinases for hyper phosphorylation, there are also distinct workplaces in various kinases such as Protein Kinase C, Protein Kinase An, ERK2, Serene/Threonine Kinase, Caspase 3 and Caspase 9 which may be introduced in Aβ. (Delgado-Morales, Agís-Balboa, Esteller, & Berdasco, 2017).

Chapter 8 Traditionally used pharmacological base of plants for neurodegeneration

Some of the plants used to address the side effects of psychiatric disorders such as AD and plants that suggested workouts that could assist with ads are discussed below. Various other plants have demonstrated substantial results equivalent to intellectual masses or relevant pharmacological exercises suggesting the possibility for use in ND care.

Table 1: Some plants and isolated compounds with important action for ND therapy (Valery L. Feigin et al., 2019)

Plant	**Compounds isolated**	**Traditional uses, pharmacological and clinical effects**
Bacopa monniera Wettst	Activity components need further study, but bacosides A and B can lead to activity (saponins)	In Ayurvedic medicine, *Bacopa monniera* has been used to strengthen memory and mind. The extract of Bacopa monniera is reported to promote learning and to

		demonstrate antioxidant effects in the cortical area of the rat, in striatum and hippocampus. (A. Bhattacharya, Ghosal, & Bhattacharya, 2001). *Bacopa monniera* also improved acquisition (Vohora, Pal, & Pillai, 2000) memory in mice which was treated with phenytoin and this one increased rats' success in different learning scenarios (Singh & Dhawan, 1982). Furthermore, *Bacopa monniera* may enhance human cognitive processes (Howes, Perry, & Houghton, 2003).
Biota orientalis Endl.	Active compounds are unknown	For insomnia and amnesia, *Biota orientalis* is used in TCM. An herbal recruitment (S-113m) made up of *Biota orientalis*, ginseng and chinensis better recording and storage of the memory (instead of the retrieval of memories) in mouse (Hiltunen, Dastmalchi, Vuorela, & Dorman, 2007). *Biota orientalis* Seed extract has strengthened the stroke of amygdala and basal forebrain lesions in mice.
Codonopsis pilulosa Franch.	Active compounds are unknown	In TCM, the root of codonopsis is used for various diseases, including amnesia, and is considered to improve blood pressure and vitality (Duke, J.A. and Ayensu, 1985). *Codonopsis pilulosa* Extract decreased memory consolidation dysfunction in vivo and showed nootropic impact (He et al., 2014).

Tetradium ruticarpum	Rutaecarpine and dehydroevodiamine (alkaloids) and limonine (nor-triterpenoid)	For cardiotonic and analgesic effects, *tetradium ruticarpum* is used in TCM. *Tetradium ruticarpum* and dehydro-evodiamine inhibited AChE in vitro, and reversed scopolamine-induced memory impairment in rats. Dehydroevodiamine increased cerebral blood flow in vivo (Carlson et al., 2007).
Hypericum perforatum L. and Hypericum calycimum L.	Hypericin and hyperforin (quinones)	*Hypericum perforatum* is used for its soothing effects in Portuguese folk medicine and neurological problems in Turkey (Ross, 2001). Increased memory and improving and fully reversed amnesia from scopolamine in micron, Hyperforin (and Hyperforatum) suggest that the cognitive capacity could be increased Hyperforin (Perfumi, Mattioli, Forti, Massi, & Ciccocioppo, 2005). Hypericum perforatum extract has also shown antioxidant activity in vitro (Zheng & Wang, 2001), in vivo anti-inflammatory and in vivo anti-inflammatory effects (Öztürk, Aydin, Beis, Başer, & Berberoğlu, 1996). *Hypericum perforatum* and hypericum was as effective as antidepressant medication (e.g. desipramine) in animal models (Öztürk et al., 1996). *Hypericum perforatum* have an effect on

		neuronal 5-HT absorption and increases both the 5-HT and noradrenaline transmission of visceral brain circuits of the forebrain, which are essential for mood regulation (Misane & Ögren, 2001). Meta-analyzes and comprehensive analyses of recorded tests reveal that for the treatment of mild / moderate depressants, *hypericum perforatum* is more realistic than placebo, and in certain situations, is equivalent to basic antidepressants (Whiskey, Werneke, & Taylor, 2001).
Magnolia officinalis	Honokiol and magnolol (biphenolic lignans)	The bark of the base and trunk *of Magnolia officinalis* was used in TCM to relieve nervous agitation and disruptions (KURIBARA, KISHI, HATTORI, OKADA, & MARUYAMA, 2000) And their potential for GABAergic neurotransmission is due to magnol (Squire et al.,1999). Antidepressant in vivo was traditional Chinese drug (Banxia Houpu), made from Pinellia ternata, Poria cocos, Magnolia officinalis and Zinziber officinale. (Luo et al.,2000). ChAT activity is increased and activity in AChE increased, in vitro and hippocampal ACh release increased (Hou, Lee Chao, & Chen, 2000). Magnolia officinalis extract (Zhou and Xu, 1992), honokiol (Chiu, Ho, Wei, Lui, & Hong, 1997) and magnolol (Y. L. Chen et al., 2001), helps in antioxidant production and in-vitro

		neurons shielded from magnolol are documented to have chemical hypoxic damages or necrotic necrobiosis (Lee e tal.,1998). Magnolol displayed in vitro and in vivo anti-inflammatory activity, possibly by COX and LOX inhibition (WANG, HO, CHANG, & CHEN, 1995).
Artemisia absinthium L.	Compounds responsible for displacement of nicotine receptor binding are unknown	In European medicine, *artemisia absinthium* has historically been used as a restorative of cognitive function lost or reduced. *Artemisia absinthium's* rudimentary alcohol extract displaced nicotine in a concentrations-dependent way to nicotine receptors (E. Perry & Howes, 2011) (Soodi, Naghdi, Hajimehdipoor, Choopani, & Sahraei, 2014).

8.1 *Centella asiatica*

Centella Ayiatica (Umbelliferae) is a rejuvenating spice that strengthens fear and memory. This leaf is ancient Ayurvedic remedy. It is responsible for recovering young people, memory and life (Kapoor, 1990). An Ayurvedic meaning of four spices. The spice, along with milk is used to boost the memory of age or forestall dementia (Manyam, 1999). The spice is often used as a sound for impotent assimilation and distress; the latter may alleviate symptoms. C. Asiatica is also used to overcome physical and emotional tiredness in TCM (Brinkhaus, Lindner, Schuppan, & Hahn, 2000) (Duke, 1985).

The oil has been extracted from the plant (0.1% of the plant) which contains monoterpenes and sesquiterpenes. The monoterpenes found in the simple oil. Bornyl acetic acid - pinene, pinene and - terpinene are incorporated in Asiatica (Agrawal, 2013), popular for controlling AChE (Miyazawa, Watanabe, & Kameoka, 1997) (PERRY, HOUGHTON, THEOBALD, JENNER, & PERRY, 2000) (Ryan & Byrne, 1988). In addition, from C. asiatica isolation of different alkaloids has been done.

A study into the pharmacological premises of the supposed anti-amnesic effect focus of the liquor of the leaves sedates in mice, a step due to a triterpene, brahmoside (Sakina & Dandiya, 1990). The study on mice found that leaf extract was relaxing, strong and cholinomimetic, obstructed by atropine activity (Sakina & Dandiya, 1990). These findings show C. Asiatica can be helpful for the patients with symptoms of suffering from AD and would also improve cholinergic movement and intellectual ability afterwards. The tool continues to be created for the potential cholinergic effect of the spice. An aqueous extract of C. asiatica enhanced rodent recall learning and dopamine modified, 5-hydroxytryptamine (5-HT) and rodent in vivo noradrenaline systems (Nalini, Aroor, Karanth, & Rao, 1992). These findings suggest that the more polar blends that are found in C. asiatica (perhaps triterpene saponins). By impacting CNS synapse framework, the Asian leaf can boost intellectual ability. The Asian triterpene is corrosive and its subordinates were obvious to defend in vitro cortical neurons from glutamate-driven excitotoxicity. (Lee et al., 1998). It is important to affirm further examinations to acknowledge the future value of ND therapy.

8.2 *Ginkgo biloba L*

Ginkgo biloba (Coniferae) was used in TCM for breathing and its application in western pharmaceutical experiments in the 1960s for circulatory disorders (Kenner and Requena, 1996). G. biloba was typically used to boost cognitive decrease due to deviations in blood flow from normal (Jr & Smith, 2017). G. biloba has been subject to numerous studies about its potential in intellectual problems in Iran in general. The G. Biloba, EGb 761 elimination has shown perfect implications for brain dissemination and digestion of neurons (Shaheen, Ali, Alqarawi, & Bashir, 2000) (Löffler et al., 2001) (Zagzoule & Marc-Vergnes, 1986), on the muscarinic cholinergic framework (Krištofiková, Benešová, & Tejkalová, 1992), also, applied movement of cancer preventive agents (Barth, Iselmann, Engemann, & Heidemann, 1991) (Marcocci, Packer, Droy-Lefaix, Sekaki, & Gardès-Albert, 1994) (Topic et al., 2002). EGb761 was also in vitro neuroprotective to the poisonousness of amyloids and NOs. (Bastianetto et al., 2000). G. biloba furthermore, extricates were tested for their effect on intellectual ability. G. biloba prevents amnesia in rodents caused by constricted scopolamine (Chopin and Briley, 1992), upgraded memory maintenance in youthful and old rodents (Petkov et al., 1993) and improved fleeting memory in mice's (Kaschel, 2011). The viability of G. biloba was observed, including EGb 761, (intellectual ability improvement) in various exams, including randomized, double-visual disability and bogus managed treatment, multi-

focused preliminary exams, following organization AD and non-AD patients (Hofferberth, 1994) (Kanowski, Herrmann, Stephan, Wierich, & Hörr, 1996) (Le Bars, Kieser, & Itil, 2000). However, the movements may be due to the vasodilative flavonoids, while various action mechanisms may also be responsible for perfect impacts. The mixtures responsible for these sensations require further analysis. Ginkgolide B from G. biloba is the enemy of the PAF (Koltai, Hosford, Guinot, Esanu, & Braquet, 1991), which demonstrates action against provocative measures. It's clear the G. Biloba may be effective for the treatment of AD manifestosis, but more studies should also be considered to discern acceptable dosing schemes, future long-term effects, interactions with other drugs and concentrates normalization.

8.3 *Salvia lavandulaefolia Vahl.* and *Salvia officinalis L*

Analysis of authentic writing has shown that many sages' exercises, notably their functions is useful for the memory, could apply to ND treatment (E. K. Perry, Pickering, Wang, Houghton, & Perry, 1998). In the late 16th century, Gerard spoke in natural English of the wise, 'it's helpful to the mind and mind individually to quicken the nerves and the brain.' Culpeper says 50 years after the fact that the memory, heating and animation of faculties often mends," while Hill in 1756 embodies the regrettable results associated with maturation by stating, "Wisdom impedes that the rapid progression of redness that takes place so fast on our heels in the last years of our lives, can preserve the workers and memory more necessary for the outdoor condition (N. S. L. Perry et al., 2001). These antique records, along with current uses, prove that wise can be soothing and that symptoms associated with estrogen unevenness can be mitigated. (Angerhofer, 2002), Recommend that the know-how in AD may be imaginable. Different testing of the impacts of sage-focused concentrate on a part of components contributing to AD or decreased in vitro and in vivo have been used.

The steam-refined oil is a different ethanol. For action against ChE, *lavandulaefolia* (Labiatae) extract is examined. It was observed that AChE was observed in very low concentration by all three examples (PERRY et al., 2000).

The barrier to cholinesterase existed on the plant extract. The cyclic monoterpenes 1,8-cineol and a-pinene that seemed to restrict AChE in vitro were possibly supposed to have *lavandulaefolia* oil with some of the commitments of many constituents, perhaps by their synergistic action (E. Perry & Howes, 2011). However, monoterpenes, by a factor of 103 in any case, were slightly less dynamic as the physostigmine inhibitors (E. Perry & Howes,

2011). The inhibitory exercises of the main terpenic components were also found not to quickly reflect the inhibitory effect of the whole *S. lavandulaefolia*. It has been estimated, if the measurement of the product terpenes is taken solely into account, half compound restraints for the oil would occur at approximately 160 mg/L−multiple times the centralization of the base oil (0.03 mg/L). These recommended, either, that the consolidated operation of terpenes had a severe degree of cooperative capacity, or more uncertainly, that an oil had an until now unknown minor high intensities portion.

In vitro movement of cancer prevention agents an aqueous extract can be used. Conditionally suppressed lipid peroxidation section of officinalis (Hohmann et al., 1999). In this plant, multiple blends of cancer prevention agents were found. Bureau, like corrosive coffee, carnosic corrosive, carnosic, corrosive rosemarinic (M. Wang et al., 2000), salvianolic acids L, I and K and different other phenolic mixes (M. Wang et al., 1999). Frail cancer prevention agent impacts were additionally demonstrated to be available in an ethanol concentrate of *S. lavandulaefolia* (10 μM of propyl gallate when compared to standard cell reinforcement), and both the water-dissolvable and chloroform-solvent portions of this concentrate gave comparative action (N. S. L. Perry et al., 2001).

Potential effects of eicosanoid mixture were observed in vitro. Concentrate of ethanol extract from *S. Lavandulaefolia* has been shown to have an nonpotential eicosanoid amalgam, which only hinders thromboxane-B2 (TXB2) for around 10 percent; but it has more (60 percent) hindrance (LTB4) blending; ethanol removal fraction was intended as a chloroform-dissolvable section, and water-solvent fraction. (N. S. L. Perry et al., 2001).

Table 2: Inhibition of acetylcholinesterase by extracts and oils (Valery L. Feigin et al., 2019)

Plant extract/compound	Assay concentration	% Inhibition (TSD) Positive controls
Tacrine	2.0 × 10—2 μM	50 T 0.1
Physostigmine	4.5 × 10—2 μM	50 T 0.1
Test substances		
S. officinalis oil	0.1 μg/mL	52.4 T 0.8
S. officinalis ethanol extract (dried)	2.5 mg/mL	68.2 T 15.6
S. lavandulaefolia oil	0.1 μg/mL	63.0 T 3.7

Hexane and chloroform concentrate of S. officinalis portion conditionally restrained croton oil-actuated ear oedema in mice, with the fundamental dynamic compound being distinguished as ursolic corrosive, yet the methanol removes and the basic oil were significantly less dynamic (Baricevic et al., 2001). The basic oil constituents of *S. lavandulaefolia* have additionally been assessed for mitigating impacts. The *S. lavandulaefolia* oil constituent a-pinene (containing 5% of the fundamental oil) was the main constituent present which gave critical action (52% hindrance at 200 µM) and indicated frail selectivity for restraint of LTB4 age. LTB4 is created by means of the chemical 5-lipoxygenase (5-LOX), the quality of which is upregulated during neurodegeneration and despite the fact that the part of this fiery arbiter in AD isn't totally evident, specific restraint over cyclo-oxygenase (COX) might be significant remedially (Sugaya, Uz, Kumar, & Manev, 2000).

Osteogenic movement in vitro: Portion subordinate osteogenic action was available in the ethanol extract (which seemed, by all accounts, to be packed in the water-dissolvable part) of S. lavandulaefolia (N. S. L. Perry et al., 2001). The osteo-genic (fragile in correlation with the normal osteogenic compound, 17 µ-estradiol) was contained in lavandulaefolia, an essential oil tested, geraniol only (0,1 mM -2 mM, c1% of basic oil) (1000 nm.) (N. S. L. Perry et al., 2001). Further analysis is expected of the possible osteogenic impact of the professional concentrates and essential oil components.

Clinical and in vivo studies: Oral S. lavandulaepholia basic oil (in a regular portion of sunflower oil) was observed in striatum and in comparison with regulated rodents on striatum and hippocampus (controlled sunflower oil alone when daily for 5 days to rye, with decreased striatal AChE moving by dosages of 20µL and 50µL; S. lavandulaefolia handled selection reviewed with the category of references (N. S. L. Perry et al., 2001).

Until now, there has been a lot of clinical study on AD patients, but a pending report reveals the influence of sage on healthy volunteers (Tildesley et al., 2005). Twenty members obtained 50 µL, 100 µL and 150 µL of a normalized oil concentrate from S. lavandulaefolia in this tamper-controlled, visually impaired, adapted, transverse configuration experiments. The vehicles (sunflower oil) and by themselves Portions were issued on separate days with the pseudo-irregular care order separated each by a 7-day wash-out period. There were various critical impacts on comprehension related with the most reduced (50 µL) portion of

Salvia. These reminiscent increases for fast and delayed word analysis scores coupled with reductions in accuracy and speed. The declines in self-assessment of "sharpness" at 2 h and "serenity" at 4 h and 6 h were linked to a similar section. After 150 μL the "serenity" and "happiness" section were lowered over the majority of time intervals. This discovery is the first orderly confirmation of Salvia's preparation and understanding in strong young people to be controlled intensely.

8.4 *Withania somnifera*

One of the most widely regarded spices in ayurvedic medicines is W. somnifera (Solanaceae) root (ashwagandha), which is used around 4000 years ago. It is known as a rejuvenated tonic ("Rasayanas"), underlined by the Ayurvedic researcher Charaka (10BC), who defined W. somnifera, 'One gets a life cycle, restores young adults, gets a good memory, wisdom and illness freedom, a shining look and a strong pony (Vineet et al., 2019). The spice is often commonly used to treat burns, such as articular inflammation. It is considered that nicotine is present in *W. Somnifera* root but a few tests did not classify its consistency (Das, Malhotra, & Prasad, 1964). Nicotine's involvement may justify W's rumored behavior. Somnifera in Ayurvedic drugs in view of the fact that nicotine is correlated with intellectual upgrade and AD insurance (Cataldo, Prochaska, & Glantz, 2010) (Newhouse & Kelton, 2000) (Sahakian, Jones, Levy, Gray, & Warburton, 1989) (Ghosal et al., 1989). Various experiments have been carried out on W's psychological changes. Sleepy. Sleepy. For example, some steroidal subordinates differentiated from W. Somnifera root are sitoindosides IX and X, both in young and old rodents that have increased learning and memory (Ghosal et al., 1989). The components to this impact are indistinct, but may include cholinergic neurotransmission balance, provided that microbes have been dominated by a concentrate which contains the sitoindosides VII‑X and withaferin (an anolide aglyconous steroid additionally from the W. somnifera root). The findings showed that the focus improved ACHE activity in the horizontal septum and globus pallidus, decreased ACHE activity in the vertical slanting strand, enhanced muscarinic M1 authoritarian receptor in parallel and in the medium septum, and increased muscarinic M2 receptor in cortical districts that did not affect y-aminobutyric co-receptors (Schneider, Farlow, & Pogoda, 1997). The target containing VII-X and withaferin A sitoindosides also reversed the initiated psychological deficit of ibotene corrosive and decreased cholinergic markers (e.g. ACh, ChAT) in rodents (S. K. Bhattacharya, Bhattacharya, Kumar, & Ghosal, 2000). The rumored interpretation of W's

effects. Somniferous origins in cortical and Basal forebrain cerebral regions engaged with intellectual ability may be clarificated by a specific activity in cholinergic neurotransmission. Those perceptions show the potential in AD care for the sitoindosides VII–X and withaferin A. The *W. somnifera* also turned the securing and treatment disruption initiated by scopolamine and constricted amnesia after electronic stuns, symptoms which could be blamed with a nootropic effect on the root separately (Dhuley, 1997). A concentrate of methanol from *W. Somnifera* root section of human neuroblastoma cells conditionally progressed dendrite growth in vitro (Tohda, Kuboyama, & Komatsu, 2000). Chances of this effect occuring in the CNS can contribute to synaptic production in AD patients with root concentrates, which involves neuritis outgrowth. A *W. somnifera* root extract also appears to fundamentally decrease the amount of declining rodent-focused, hippocampal cerebral locale cells which suggest that root concentrate may have anticipated neurodegenerative effects (Jain, Shukla, Sharma, & Bhatnagar, 2001). The glycoitanolides demonstrated anxiolytic and upper exercises in rodents (S. K. Bhattacharya, Bhattacharya, Sairam, & Ghosal, 2000), which might be relevant in the indicative treatment of AD. Sedating and propensity for barbiturate, ethanol and urane initiated spellbinding in mouse have resulted in vivo from an alkaloid extracted (Malhotra, Mehta, Das, & Dhalla, 1965). The pharmacological reasons for these perceptions are unclear, but may reflect the comprehensive influence of GABA mimetic W. somnifera extract (Mehta, Binkley, Gandhi, & Ticku, 1991). W. Somnifera root and a few components also have cancer prevention agents and relaxing activities that are also relevant for treatment with AD. The non-refined concentrate is used to inhibit in vitro and in vivo lipid peroxidation (Dhuley, 1997). The root separation and glycowithanolides (which consist of sitoindoside equimolars VII–X and with warfarin). These are hepatoprotective in rodents and mice and have an effect against hepatic lipid peroxidation on the cell reinforcement movements. (A. Bhattacharya, Ramanathan, Ghosal, & Bhattacharya, 2000). The mixes liable for cell reinforcement movement incorporate with anolides (A. Bhattacharya et al., 2001) (Mishra, Singh, & Dagenais, 2000) (Hiltunen et al., 2007). However, cancer prevention agents can also be separate blends in the root. The Glycoethanolides reduced the lipid peroxidation of different tissues which recall the mind of rodents and the Catalases and the Glutathione Peroxidase exercises in the frontal rodents and striatum were increased, both by the glycoethanolides and sitoindosides (Ghosal et al., 1989) (A. Bhattacharya et al., 2001) (Chaurasia, Panda, & Kar, 2000). A root extract was successful against joint pain in the experimented rodents (Hazeena Begum & Sadique, 1988) and diminished serum protein levels (for example a2-macroglobulin, a marker of inflammatory conservative conditions)

(Anbalagan & Sadique, 1985), and in a twofold visually impaired, fake treatment controlled, traverse study, treatment in patients with osteoarthritis brought about an improvement in manifestations (Kulkarni, Patki, Jog, Gandage, & Patwardhan, 1991). W. somnifera the IL-1 and TNF-a levels decreased somnifera to the mice treated with a cancer causant (Dhuley, 1997), that may also be used against AD, taking into account the potential combination of the decrepit plaque and neurodegeneration of these inflammatory conservative arbiter. W. somnifera leaves also obtain a remedial action (Sudhir et al., 1986). The root extract of the W. somnifera indicates that this may have multiple beneficial effects on AD patients; the good circumstances of a non-adulterated concentrate mixture can likewise be stressed compound.

8.5 *Semecarpus anacardium L. f*

Anacardium Semecarpus L. f. A family of anacardiaceaes is a place, typically referred to in the plants as 'Ballataka,' or 'Bhilwa,' which are infamous for its restorative reward in medication agreements for Ayurvedic and Siddha, the detoxified nut of *S. anacardium* was in Ayurveda, used as a remedy for skin diseases, tumours. It is still used since time immemorial for non-therapy uses such as object stamping, hair colour and so on. Phytochemical tests from *S. anacardium* indicate a variety of organically dynamic mixtures, including bioflavonoid, also available phenolic, phenol, mineral, vitamin and amino acid. Several experiments on stimulation, immunomodulation, hypocortisolemia, enhancing cells, supernal function, anti-sperm movement, advertisement behavior for hair growth and so on have been carried out according to Shukla et al., which demonstrated a vital neuron cell degeneration arising from immobilization tension in the two pyramidal (CA2) and hippocampal subregional granule cells (Dg). The existence of essential amounts of dim cell bodies in both locations was suggested by light-infinitesimal examinations. Following treatment with the concentrate of SA, there was a complete decrease in the amount of degrading cells in the pyramid (CA2) and granule cell layers (Dg), investigated CNS impacts of SA nut milk concentrate in different test creature models in loco and nootropic exercises. The absence of the synapse ACh is combined with a loss of cholinergic cells, particularly in the basal forebrain. The *S. anacardium* works by preventing the cleavage of the ACh by reducing AchE. *S. anacardium* is considered to be effective in the therapy, memory improvement or associated CNS of psychological deterioration.

Chapter 9 Methodology



Chapter 10 Discussion

The neurodegeneration mechanism is not fully known and for this there is no proper treatment yet for the disorders derived from it. Investigators use animal disease model to check alternative therapeutic agents in the search for successful therapy (as against palliative care). Cheap and relatively fast means for two core functions are given by model organisms: target recognition and target validation (Marsh et al., 2009). Together this serves to demonstrate the importance of such medications and recovery methods by striving to improve the seriousness of the disease. One example is Medivation, Inc., the medication Dimebon. In the year 2009, this medicine was being used in the phase three, clinical trials in AD and also in phase II clinical trials in HD (Marsh et al., 2009). The findings of a scientific phase III test were published in March 2010, and Dimebon, a research medication with AD did fail in the deciding connectivity trial of medium to critical disease patients (Dimebon Disappoints in Phase 3 Trial, ALZFORUM, n.d.). Dimebon (Latrepirdine) failed in 2012 during the ongoing Medivation three and Pfizer clinical trial done for AD. The case concluded successfully during this indication (Sweetlove, 2012). In another trial with an AD rat model, the systemic use of (PRP)-1 which is known as hypothalamic which is rich with proline peptide, has shown some neuron protective effects and can inhibit the neurodegeneration of amyloid-beta limbic system from the age of 25 to 35. The trial suggests us that PRP-1 therapeutic benefit could be available (Galoyan et al., 2008).

The clinical treatment of protein degradation provides both stopping abnormal proteins from synthesizing and degradation. Upregulation of the autophagy will help in clearing the protein clusters involved in the neural degeneration is also a thing to be concerned about. Both alternatives have very complicated routes, which we can only imagine (Rubinsztein, 2006).

The point of this immunotherapy is to improve this neural system facets. Not only the active and but also the passive vaccines and other requirements are proposed; however more studies should be carried out to show protection and effectiveness in humans (Pastorino et al., 2004). The protease β-secretase is an existing clinical goal in the treatment of DA (Brody & Holtzman, 2008) which is therefore involved in the amyloidal starchlike farinaceous starchy amylaceous mechanism that contributes to protein pathologies within the brain. When the amyloid protein (APP) coding gene is broken with α-secretase (Schenk, Basi, & Pangalos, 2012) The toxic protein β-amyloid is not made, rather than β-secretase. Unique inhibition

(Esch et al., 1990) The neuronal death responsible for signs of AD will likely be avoided by β-secretase.

Now the possible reasons behind the ND are genetic, protein misfolding, intracellular mechanism, programmed cell death and transglutaminase. *Centella asiatica* is responsible for recovering young people, memory and life. It is an ayurvedic herb used along with milk to boost the memory of age or forestall dementia. The improved rodent reminder of information and adjusted dopamine, 5-hydroxytryptomine (5-HT) and noradrenaline rodents in vivo is an aqueous extract of this herb. The more polar blends found in the plant these results indicate (perhaps triterpene saponins). The Asian leaf will increase intellectual potential by influencing the CNS synapse system. In vitro cortical neurons were clearly protected by the Asian triterpenic corrosive and its subordinates against glutamate-driven excitotoxicity. Further exams can help to identify the future importance of ND therapy are necessary.

Here, the *Bacopa monniera* can help improving the cognitive processes in humans. *Biota orientalis* seed extract enhances the memory acquisition disorders induced by amygdala and also basal forebrain lesions in mice. So, the extract can be used as a potential neuroprotective agent. The Magnolia *officinalis* is being used in TCM for treating nervous disturbances and anxiety. For these reasons, it can be further researched for finding a proper medication against ND. *Ginkgo biloba* extract used for the EGb 761 elimination has shown perfect implications for brain dissemination and digestion of neurons on the muscarinic cholinergic framework. Furthermore, extricates were tested for their effect on intellectual ability. It prevents amnesia in rodents caused by constricted scopolamine, upgraded memory maintenance in youthful and old rodents and improved fleeting memory in mice. This can be further tested for using in the treatment of PD and AD.

Withania somnifera increase the chances of its effect occurring in the CNS to synaptic production in AD patients with root concentrates, which involves neuritis outgrowth. Cholinergic potential mice could be improved afterward. A W. somnifera root extract also appears to fundamentally decrease the amount of declining rodent-focused, hippocampal cerebral locale cells which suggest that root concentrate may have anticipated neurodegenerative effects. The results of this plant study suggest that it can also be used for human AD. The main problem related to AD is the damage or necrosis of the neurons. This however can be overcome using the extracts found from this W. somnifera.

Semecarpus anacardium L. f, S. officinalis have indicated impacts on memory, further investigations with respect to the mixes answerable for movement are fundamental. To distinguish which mixes are liable for the pharmacologic uses are noticed and also if intensifies act synergistically to improve action. A large number of the plants and mixes that have exhibited exercises pertinent to AD treatment, the clinical information is extremely restricted. In a study, twenty members obtained 50 L, 100 L and 150 L of a normalized oil concentrate from *S. lavandulaefolia*. The vehicles (sunflower oil) and by themselves Portions were issued on separate days with the pseudo-irregular care order separated each by a 7-day wash-out period. There were various critical impacts on comprehension related with the most reduced (50 L) portion of Salvia. This study gives a positive result that it can be used for the potential use against AD.

Lastly, *Artemisia absinthium* was used traditionally in European medicine as a restorative of lost or declining cognitive function. This plants alcohol extract displaced nicotine in a concentrations-dependent way to nicotine receptors which frees the nicotine receptors and that can be also be an indication to be used in the ND's potential treatment research. This plants extracts can be identified and researched for finding more potent medication.

Herbal plants are extremely rich with phytochemicals and other dynamic constituents which are liable for expanding nootropic movement. The rising instances of neurodegenerative problems and helpless comprehension of its instrument of advancement and pathogenesis ruins analysts in creating legitimate remedy for patients burdened with them. In lab experiments, these plants have been utilized for potential neuroprotection activity. Likewise, these plants extract and parts can be taken into account and investigated for more neuroprotective activity.

Chapter 11 Conclusion

It is clear that a number of plants will demonstrate or probably display different exercises for treatment of neurodegenerative conditions. The researches result shows that physostigmine and galantamine, have decreased the ChE alkaloids. This is perhaps an idea of the general success of AChE inhibitor use in AD patients and a lack of awareness of the obsessive elements of AD and the resulting therapy focuses. Although some plants such as *Ginkgo biloba, Semecarpus anacardium L. f, S. officinalis, Artemisia absinthium* and *Withania somnifera* have shown beneficial impacts to psychological skills, improvement of the neurons. More research on activity responsible mixes is important for deciding which mixes are responsible for noticeable pharmacological action or for intensifying the synergistic behavior to boost action. Medical knowledge is highly needed for a vast variety of plants and mixtures relating to ND treatment. Medical feasibility and possible harmfulness of complex plants and mixtures at greater preliminary levels must be further assessed prior to making recommendations on their standard application. All things considered; it is clear that plants' pharmacological exercises also tend to represent their uses in the care of individuals. The photographic methodology for the treatment of a particular disease of ND can be established. For plants to be explored a reasonably successful method needs to be identified which will help in between plants and extracts which may be used for remedial application of neurodegenerative diseases.

Chapter 12 Future Work

There is also a considerable number of plants under control research. Plants and their extracts that are clinically studied display their findings depending on the planned pharmacological device model. As ND builds up a number of physiological pathways for its growth, it is very difficult to produce positive results from a few plants. In order to accomplish this goal, different ongoing outcomes should be integrated. Also, the plants mentioned in this paper not all of them are properly explored. For this reason, these plants can be taken into lab research to find out the extracts and see which one gives the proper neuroprotective activity. It is because if the mechanism of action of these extracts can be learnt than it would be easier to find the accurate compound with neuroprotectivity.

References

Abugable, A. A., Morris, J. L. M., Palminha, N. M., Zaksauskaite, R., Ray, S., & El-Khamisy, S. F. (2019). DNA repair and neurological disease: From molecular understanding to the development of diagnostics and model organisms. *DNA Repair*, *81*(July), 102669. https://doi.org/10.1016/j.dnarep.2019.102669

Agrawal, P. K. (2013). Natural Product Communications: Editorial. *Natural Product Communications*, *8*(6).

Alam, M. B. (2017). Neurological Disease Burden: Bangladesh Perspective. *Journal of National Institute of Neurosciences Bangladesh*, *1*(2), 31–32. https://doi.org/10.3329/jninb.v1i2.29834

Alzheimer's disease - Causes - NHS. (n.d.).

Anbalagan, K., & Sadique, J. (1985). Withania somnifera (ashwagandha), a rejuvenating herbal drug which controls alpha-2-macroglobulin synthesis during inflammation. *Pharmaceutical Biology*, *23*(4), 177–183. https://doi.org/10.3109/13880208509069028

Angerhofer, C. K. (2002). Herbal Medicines, a Guide for Healthcare Professionals, Second Edition By Joanne Barnes (University of London), Linda A. Anderson (Medicines Control Agency, London), and J. David Phillipson (University of London). Pharmaceutical Press, London, UK. 2002. xiv + 530 pp. 18.5 × 24.5 cm. $59.95. ISBN 0-85369-474-5. *Journal of Natural Products*, *65*(12), 1964–1964. https://doi.org/10.1021/np0207320

Aziz, N. A., Van Der Marck, M. A., Pijl, H., Olde Rikkert, M. G. M., Bloem, B. R., & Roos, R. A. C. (2008). Weight loss in neurodegenerative disorders. *Journal of Neurology*, *255*(12), 1872–1880. https://doi.org/10.1007/s00415-009-0062-8

Baricevic, D., Sosa, S., Della Loggia, R., Tubaro, A., Simonovska, B., Krasna, A., & Zupancic, A. (2001). Topical anti-inflammatory activity of Salvia officinalis L. leaves: the relevance of ursolic acid. *Journal of Ethnopharmacology*, *75*(2–3), 125–132. https://doi.org/10.1016/S0378-8741(00)00396-2

Barreto, G. E., Iarkov, A., & Moran, V. E. (2015). Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease. *Frontiers in Aging Neuroscience*, *7*(JAN), 1–13. https://doi.org/10.3389/fnagi.2014.00340

Barth, S. A., Iselmann, G., Engemann, R., & Heidemann, H. T. (1991). Influences of Ginkgo biloba on cyclosporin a induced lipid peroxidation in human liver microsomes in comparison to vitamin E, glutathione and N-acetylcysteine. *Biochemical Pharmacology*, *41*(10), 1521–1526. https://doi.org/10.1016/0006-2952(91)90570-U

Bastianetto, S., Ramassamy, C., Doré, S., Christen, Y., Poirier, J., & Quirion, R. (2000). The ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid. *European Journal of Neuroscience*, *12*(6), 1882–1890. https://doi.org/10.1046/j.1460-9568.2000.00069.x

Beeldman, E., Raaphorst, J., Twennaar, M. K., De Visser, M., Schmand, B. A., & De Haan, R. J. (2016, June). The cognitive profile of ALS: A systematic review and meta-analysis update. *Journal of Neurology, Neurosurgery and Psychiatry*. BMJ Publishing Group. https://doi.org/10.1136/jnnp-2015-310734

Bhattacharya, A., Ghosal, S., & Bhattacharya, S. K. (2001). Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. *Journal of Ethnopharmacology*, *74*(1), 1–6. https://doi.org/10.1016/S0378-8741(00)00309-3

Bhattacharya, A., Ramanathan, M., Ghosal, S., & Bhattacharya, S. K. (2000). Effect of Withania somnifera glycowithanolides on iron-induced hepatotoxicity in rats. *Phytotherapy Research*, *14*(7), 568–570. https://doi.org/10.1002/1099-1573(200011)14:7<568::AID-PTR663>3.0.CO;2-Q

Bhattacharya, S. K., Bhattacharya, A., Kumar, A., & Ghosal, S. (2000). Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. *Phytotherapy Research*, *14*(3), 174–179. https://doi.org/10.1002/(SICI)1099-1573(200005)14:3<174::AID-PTR624>3.0.CO;2-O

Bhattacharya, S. K., Bhattacharya, A., Sairam, K., & Ghosal, S. (2000). Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: An experimental study. *Phytomedicine*, *7*(6), 463–469. https://doi.org/10.1016/S0944-7113(00)80030-6

Bilgiç, B., Hanağası, H. A., & Emre, M. (2010). Parkinson's disease dementia. *Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management*, *363*, 177–191.

https://doi.org/10.1017/CBO9781139856669.017

Blood Pressure and Alzheimer's Risk: What's the Connection? | Johns Hopkins Medicine. (n.d.).

Blum, K., Badgaiyan, R. D., Dunston, G. M., Baron, D., Modestino, E. J., McLaughlin, T., … Gondré-Lewis, M. C. (2018). The DRD2 Taq1A A1 Allele May Magnify the Risk of Alzheimer's in Aging African-Americans. *Molecular Neurobiology*, *55*(7), 5526–5536. https://doi.org/10.1007/s12035-017-0758-1

Botanical Medicine: A European Professional Perspective - Dan Kenner, Yves Requena - Google Books. (n.d.).

Bredesen, D. E., Rao, R. V., & Mehlen, P. (2006). Cell death in the nervous system. *Nature*, *443*(7113), 796–802. https://doi.org/10.1038/nature05293

Brinkhaus, B., Lindner, M., Schuppan, D., & Hahn, E. G. (2000). Chemical, pharmacological and clinical profile of the East Asian medical plant Centella asiatica. *Phytomedicine*. Phytomedicine. https://doi.org/10.1016/S0944-7113(00)80065-3

Brody, D. L., & Holtzman, D. M. (2008). Active and passive immunotherapy for neurodegenerative disorders. *Annual Review of Neuroscience*. Annu Rev Neurosci. https://doi.org/10.1146/annurev.neuro.31.060407.125529

Brown, R. H., & Al-Chalabi, A. (2017). Amyotrophic Lateral Sclerosis. *New England Journal of Medicine*, *377*(2), 162–172. https://doi.org/10.1056/NEJMra1603471

Caccamo, D., Currò, M., Condello, S., Ferlazzo, N., & Ientile, R. (2010). Critical role of transglutaminase and other stress proteins during neurodegenerative processes. In *Amino Acids* (Vol. 38, pp. 653–658). Amino Acids. https://doi.org/10.1007/s00726-009-0428-3

Çamcı, G., & Oğuz, S. (2016). Association between Parkinson's disease and Helicobacter pylori. *Journal of Clinical Neurology (Korea)*, *12*(2), 147–150. https://doi.org/10.3988/jcn.2016.12.2.147

Carlesimo, G. A., & Oscar-Berman, M. (1992). Memory deficits in Alzheimer's patients: A comprehensive review. *Neuropsychology Review*, *3*(2), 119–169. https://doi.org/10.1007/BF01108841

Carlson, J. J., Farquhar, J. W., DiNucci, E., Ausserer, L., Zehnder, J., Miller, D., … Haskell,

W. L. (2007). Safety and Efficacy of a Ginkgo Biloba-Containing Dietary Supplement on Cognitive Function, Quality of Life, and Platelet Function in Healthy, Cognitively Intact Older Adults. *Journal of the American Dietetic Association*, *107*(3), 422–432. https://doi.org/10.1016/j.jada.2006.12.011

Caron, N. S., Wright, G. E., & Hayden, M. R. (1993). *Huntington Disease*. *GeneReviews®*. University of Washington, Seattle.

Cataldo, J. K., Prochaska, J. J., & Glantz, S. A. (2010). Cigarette smoking is a risk factor for Alzheimer's disease: An analysis controlling for tobacco industry affiliation. *Journal of Alzheimer's Disease*, *19*(2), 465–480. https://doi.org/10.3233/JAD-2010-1240

Chahine, L. M., Stern, M. B., & Chen-Plotkin, A. (2014). Blood-based biomarkers for Parkinson's disease. *Parkinsonism and Related Disorders*, *20*(SUPPL.1), S99–S103. https://doi.org/10.1016/S1353-8020(13)70025-7

Chaurasia, S. S., Panda, S., & Kar, A. (2000). Withania somnifera root extract in the regulation of lead-induced oxidative damage in male mouse. *Pharmacological Research*, *41*(6), 663–666. https://doi.org/10.1006/phrs.1999.0634

Chen, J. X., & Yan, S. S. (2010). Role of mitochondrial amyloid-β in Alzheimer's disease. *Journal of Alzheimer's Disease*, *20*(SUPPL.2). https://doi.org/10.3233/JAD-2010-100357

Chen, S. Y., & Tsai, S. T. (2010). The epidemiology of Parkinson's disease. *Tzu Chi Medical Journal*, *22*(2), 73–81. https://doi.org/10.1016/S1016-3190(10)60044-4

Chen, Y. L., Lin, K. F., Shiao, M. S., Chen, Y. T., Hong, C. Y., & Lin, S. J. (2001). Magnolol, a potent antioxidant from Magnolia officinalis, attenuates intimal thickening and MCP-1 expression after balloon injury of the aorta in cholesterol-fed rabbits. *Basic Research in Cardiology*, *96*(4), 353–363. https://doi.org/10.1007/s003950170043

Chiò, A., Mora, G., & Lauria, G. (2017, February). Pain in amyotrophic lateral sclerosis. *The Lancet Neurology*. Lancet Publishing Group. https://doi.org/10.1016/S1474-4422(16)30358-1

Chiu, J. H., Ho, C. T., Wei, Y. H., Lui, W. Y., & Hong, C. Y. (1997). In vitro and in vivo protective effect of honokiol on rat liver from peroxidative injury. *Life Sciences*, *61*(19), 1961–1971. https://doi.org/10.1016/S0024-3205(97)00836-9

Claeysen, S., Cochet, M., Donneger, R., Dumuis, A., Bockaert, J., & Giannoni, P. (2012). Alzheimer culprits: Cellular crossroads and interplay. *Cellular Signalling*, *24*(9), 1831–1840. https://doi.org/10.1016/j.cellsig.2012.05.008

Coleman, M. P., & Freeman, M. R. (2010). Wallerian degeneration, WldS, and Nmnat. *Annual Review of Neuroscience*. Annu Rev Neurosci. https://doi.org/10.1146/annurev-neuro-060909-153248

Council, M. R., Road, H., & Kingdom, U. (2001). Eurodegenerative auopathies. *Genetics*, 1121–1161.

Crews, L., & Masliah, E. (2010). Molecular mechanisms of neurodegeneration in Alzheimer's disease. *Human Molecular Genetics*, *19*(R1), 1–41. https://doi.org/10.1093/hmg/ddq160

CROSSMAN, A. R. (2000). Functional anatomy of movement disorders. *Journal of Anatomy*, *196*(4), 519–525. https://doi.org/10.1046/j.1469-7580.2000.19640519.x

Das, P. K., Malhotra, C., & Prasad, K. (1964). CARDIOTONIC ACTIVITY OF ASHWAGANDHINE AND ASHWAGANDHININE, TWO ALKALOIDS FROM WITHANIA ASHWAGANDHA, KAUL. *Undefined*.

Davie, C. A. (2008). A review of Parkinson's disease. *British Medical Bulletin*, *86*(1), 109–127. https://doi.org/10.1093/bmb/ldn013

Davis, A. A., Andruska, K. M., Benitez, B. A., Racette, B. A., Perlmutter, J. S., & Cruchaga, C. (2016). Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. *Neurobiology of Aging*, *37*, 209.e1-209.e7. https://doi.org/10.1016/j.neurobiolaging.2015.09.014

Davis, M. Y., Keene, C. D., Jayadev, S., & Bird, T. (2014). The Co-Occurrence of Alzheimer's Disease and Huntington's Disease: A Neuropathological Study of 15 Elderly Huntington's Disease Subjects. *Journal of Huntington's Disease*, *3*(2), 209–217. https://doi.org/10.3233/JHD-140111

Dayalu, P., & Albin, R. L. (2015, February). Huntington Disease: Pathogenesis and Treatment. *Neurologic Clinics*. W.B. Saunders. https://doi.org/10.1016/j.ncl.2014.09.003

De Vos, K. J., Grierson, A. J., Ackerley, S., & Miller, C. C. J. (2008a). Role of axonal

transport in neurodegenerative diseases. *Annual Review of Neuroscience*. Annu Rev Neurosci. https://doi.org/10.1146/annurev.neuro.31.061307.090711

De Vos, K. J., Grierson, A. J., Ackerley, S., & Miller, C. C. J. (2008b). Role of Axonal Transport in Neurodegenerative Diseases. *Annual Review of Neuroscience, 31*(1), 151–173. https://doi.org/10.1146/annurev.neuro.31.061307.090711

Delgado-Morales, R., Agís-Balboa, R. C., Esteller, M., & Berdasco, M. (2017). Epigenetic mechanisms during ageing and neurogenesis as novel therapeutic avenues in human brain disorders. *Clinical Epigenetics, 9*(1), 1–18. https://doi.org/10.1186/s13148-017-0365-z

Dementia | Dementia Congress | Dementia Conference | Alzheimer Conference | Alzheimer's Conference | Vascular Dementia Conference | Neurology Conference | Neuroscience Conferences | CME Conference | Europe| 2020. (n.d.).

Dextera, D. T., & Jenner, P. (2013). Parkinson disease: From pathology to molecular disease mechanisms. *Free Radical Biology and Medicine*, *62*, 132–144. https://doi.org/10.1016/j.freeradbiomed.2013.01.018

Dhuley, J. N. (1997). Effect of some Indian herbs on macrophage functions in ochratoxin A treated mice. *Journal of Ethnopharmacology*, *58*(1), 15–20. https://doi.org/10.1016/S0378-8741(97)00072-X

Di Giorgio, F. P., Carrasco, M. A., Siao, M. C., Maniatis, T., & Eggan, K. (2007). Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. *Nature Neuroscience, 10*(5), 608–614. https://doi.org/10.1038/nn1885

Dickey, A. S., & La Spada, A. R. (2018). Therapy development in Huntington disease: From current strategies to emerging opportunities. *American Journal of Medical Genetics Part A, 176*(4), 842–861. https://doi.org/10.1002/ajmg.a.38494

DiMauro, S., & Schon, E. A. (2008). Mitochondrial disorders in the nervous system. *Annual Review of Neuroscience*. Annu Rev Neurosci. https://doi.org/10.1146/annurev.neuro.30.051606.094302

Dimebon Disappoints in Phase 3 Trial | ALZFORUM. (n.d.).

Duke, J.A. and Ayensu, E.S. (1985) Medicinal Plants of China. Reference Publications, Inc. - References - Scientific Research Publishing. (n.d.).

Duke, J. (1985). *Medicinal plants of China*. Algonac Mich.: Reference Publications.

Eftekharzadeh, B., Daigle, J. G., Kapinos, L. E., Coyne, A., Schiantarelli, J., Carlomagno, Y., … Hyman, B. T. (2018). Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. *Neuron*, *99*(5), 925-940.e7. https://doi.org/10.1016/j.neuron.2018.07.039

Elbaz, A., Carcaillon, L., Kab, S., & Moisan, F. (2015). EPIDEMIOLOGY OF PARKINSON ' S DISEASE The Rotterdam Study. *Revue Neurologique*, *1580*(1), 1–13. https://doi.org/10.1016/j.neurol.2015.09.012

Engelberg-Kulka, H., Amitai, S., Kolodkin-Gal, I., & Hazan, R. (2006, October). Bacterial programmed cell death and multicellular behavior in bacteria. *PLoS Genetics*. PLoS Genet. https://doi.org/10.1371/journal.pgen.0020135

Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., … Ward, P. J. (1990). Cleavage of amyloid β peptide during constitutive processing of its precursor. *Science*, *248*(4959), 1122–1124. https://doi.org/10.1126/science.2111583

Estrada Sánchez, A. M., Mejía-Toiber, J., & Massieu, L. (2008). Excitotoxic Neuronal Death and the Pathogenesis of Huntington's Disease. *Archives of Medical Research*, *39*(3), 265–276. https://doi.org/10.1016/j.arcmed.2007.11.011

Feigin, V. L., Krishnamurthi, R. V., Theadom, A. M., Abajobir, A. A., Mishra, S. R., Ahmed, M. B., … Zaki, M. E. (2017). Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet Neurology*, *16*(11), 877–897. https://doi.org/10.1016/S1474-4422(17)30299-5

Feigin, Valery L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., … Vos, T. (2019). Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology*, *18*(5), 459–480. https://doi.org/10.1016/S1474-4422(18)30499-X

Forbes, R., Craig, J., Callender, M., & Patterson, V. (2004). Liaison neurology for acute medical admissions [4]. *Clinical Medicine, Journal of the Royal College of Physicians of London*. Royal College of Physicians. https://doi.org/10.7861/clinmedicine.4-3-290

Galasko, D., Salmon, D., Craig, K., Perl, D. P., & Schellenberg, G. (2002). Clinical features

and changing patterns of neurodegenerative disorders on Guam, 1997-2000 [5] (multiple letters). *Neurology*, *59*(7), 1121. https://doi.org/10.1212/wnl.59.7.1121

Galoyan, A. A., Sarkissian, J. S., Chavushyan, V. A., Meliksetyan, I. B., Avagyan, Z. E., Poghosyan, M. V., … Abrahamyan, D. O. (2008). Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Aβ25-35 model of Alzheimer's disease. *Alzheimer's and Dementia*, *4*(5), 332–344. https://doi.org/10.1016/j.jalz.2007.10.019

Gan-Or, Z., Dion, P. A., & Rouleau, G. A. (2015). Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. *Autophagy*, *11*(9), 1443–1457. https://doi.org/10.1080/15548627.2015.1067364

Ghosal, S., Lal, J., Srivastava, R., Bhattacharya, S. K., Upadhyay, S. N., Jaiswal, A. K., & Chattopadhyay, U. (1989). Immunomodulatory and CNS effects of sitoindosides IX and X, two new glycowithanolides fromWithania somnifera. *Phytotherapy Research*, *3*(5), 201–206. https://doi.org/10.1002/ptr.2650030510

Gold, D. P., Reis, M. F., Markiewicz, D., & Andres, D. (1995). When Home Caregiving Ends: A Longitudinal Study of Outcomes for Caregivers of Relatives with Dementia. *Journal of the American Geriatrics Society*, *43*(1), 10–16. https://doi.org/10.1111/j.1532-5415.1995.tb06235.x

Green, D. R., & Kroemer, G. (2005, October). Pharmacological manipulation of cell death: Clinical applications in sight? *Journal of Clinical Investigation*. J Clin Invest. https://doi.org/10.1172/JCI26321

Grundman, M., Petersen, R. C., Ferris, S. H., Thomas, R. G., Aisen, P. S., Bennett, D. A., … Thal, L. J. (2004). Mild Cognitive Impairment Can Be Distinguished from Alzheimer Disease and Normal Aging for Clinical Trials. *Archives of Neurology*, *61*(1), 59–66. https://doi.org/10.1001/archneur.61.1.59

Hazeena Begum, V., & Sadique, J. (1988). Long term effect of herbal drug Withania somnifera on adjuvant induced arthritis in rats. *Indian Journal of Experimental Biology*, *26*(11), 877–882.

He, J. Y., Ma, N., Zhu, S., Komatsu, K., Li, Z. Y., & Fu, W. M. (2014, September). The genus Codonopsis (Campanulaceae): A review of phytochemistry, bioactivity and quality control. *Journal of Natural Medicines*. Springer-Verlag Tokyo.

https://doi.org/10.1007/s11418-014-0861-9

Hermans, G. (2015). *Opening Up Design : Engaging the Layperson in the Design of Everyday Products*. *Umeå Institute of Design Research Publications* (Vol. 2).

Hiltunen, R., Dastmalchi, K., Vuorela, H., & Dorman, H. (2007). Plants as potential sources for drug development against Alzheimer's disease. *International Journal of Biomedical and Pharmaceutical Sciences*, *1*(2), 83–104.

Hobson, E. V., & McDermott, C. J. (2016, September). Supportive and symptomatic management of amyotrophic lateral sclerosis. *Nature Reviews Neurology*. Nature Publishing Group. https://doi.org/10.1038/nrneurol.2016.111

Hofferberth, B. (1994). The efficacy of EGb 761 in patients with senile dementia of the alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. *Human Psychopharmacology: Clinical and Experimental*, *9*(3), 215–222. https://doi.org/10.1002/hup.470090308

Hohmann, J., Zupkó, I., Rédei, D., Csányi, M., Falkay, G., Máthé, I., & Janicsák, G. (1999). Protective effects of the aerial parts of Salvia officinalis, Melissa officinalis and Lavandula angustifolia and their constituents against enzyme- dependent and enzyme-independent lipid peroxidation. *Planta Medica*, *65*(6), 576–578. https://doi.org/10.1055/s-2006-960830

Hölscher, C. (1998). Possible causes of Alzheimer's disease: Amyloid fragments, free radicals, and calcium homeostasis. *Neurobiology of Disease*, *5*(3), 129–141. https://doi.org/10.1006/nbdi.1998.0193

Hou, Y. C., Lee Chao, P. D., & Chen, S. Y. (2000). Honokiol and magnolol increased hippocampal acetylcholine release in freely-moving rats. *American Journal of Chinese Medicine*, *28*(3–4), 379–384. https://doi.org/10.1142/s0192415x00000441

Howes, M. J. R., Perry, N. S. L., & Houghton, P. J. (2003, January). Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. *Phytotherapy Research*. https://doi.org/10.1002/ptr.1280

Huntington disease-like 2. (2020). In *Definitions*. Qeios. https://doi.org/10.32388/lkfkvq

Jain, S., Shukla, S. D., Sharma, K., & Bhatnagar, M. (2001). Neuroprotective effects of Withania somnifera Dunn. in hippocampal sub-regions of female albino rat.

Phytotherapy Research, *15*(6), 544–548. https://doi.org/10.1002/ptr.802

Jankovic, J. (2008). Parkinson's disease: Clinical features and diagnosis. *Journal of Neurology, Neurosurgery and Psychiatry*, *79*(4), 368–376. https://doi.org/10.1136/jnnp.2007.131045

Jensen, P., Sørensen, S. A., Fenger, K., & Bolwig, T. G. (1993). A Study of Psychiatric Morbidity in Patients with Huntington's Disease, Their Relatives, and Controls. *British Journal of Psychiatry*, *163*(6), 790–797. https://doi.org/10.1192/bjp.163.6.790

Jeppesen, D. K., Bohr, V. A., & Stevnsner, T. (2011, July). DNA repair deficiency in neurodegeneration. *Progress in Neurobiology*. Prog Neurobiol. https://doi.org/10.1016/j.pneurobio.2011.04.013

Jr, J. P. S., & Smith, J. P. (2017). Digital Commons @ Humboldt State University Medical Plants - General References MEDICINAL PLANTS — GENERAL REFERENCES.

Julien, J. P. (2007, May). ALS: Astrocytes move in as deadly neighbors. *Nature Neuroscience*. Nat Neurosci. https://doi.org/10.1038/nn0507-535

Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. *The Lancet*, *386*(9996), 896–912. https://doi.org/10.1016/S0140-6736(14)61393-3

Kanowski, S., Herrmann, W. M., Stephan, K., Wierich, W., & Hörr, R. (1996). Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. *Pharmacopsychiatry*, *29*(2), 47–56. https://doi.org/10.1055/s-2007-979544

Kaschel, R. (2011). Specific memory effects of Ginkgo biloba extract EGb 761 in middle-aged healthy volunteers. *Phytomedicine*, *18*(14), 1202–1207. https://doi.org/10.1016/j.phymed.2011.06.021

Koltai, M., Hosford, D., Guinot, P., Esanu, A., & Braquet, P. (1991). Platelet Activating Factor (PAF): A Review of its Effects, Antagonists and Possible Future Clinical Implications (Part I). *Drugs*. Drugs. https://doi.org/10.2165/00003495-199142010-00002

Krištofiková, Z., Benešová, O., & Tejkalová, H. (1992). Changes of High-Affinity Choline Uptake in the Hippocampus of Old Rats after Long-Term Administration of Two Nootropic Drugs (Tacrine and <i>Ginkgo biloba </i>Extract). *Dementia and*

Geriatric Cognitive Disorders, *3*(5–6), 304–307. https://doi.org/10.1159/000107030

Kujoth, G. C., Leeuwenburgh, C., & Prolla, T. A. (2006). Mitochondrial DNA mutations and apoptosis in mammalian aging. *Cancer Research*, *66*(15), 7386–7389. https://doi.org/10.1158/0008-5472.CAN-05-4670

Kulkarni, R. R., Patki, P. S., Jog, V. P., Gandage, S. G., & Patwardhan, B. (1991). Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. *Journal of Ethnopharmacology*, *33*(1–2), 91–95. https://doi.org/10.1016/0378-8741(91)90167-C

KURIBARA, H., KISHI, E., HATTORI, N., OKADA, M., & MARUYAMA, Y. (2000). The Anxiolytic Effect of Two Oriental Herbal Drugs in Japan Attributed to Honokiol from Magnolia Bark. *Journal of Pharmacy and Pharmacology*, *52*(11), 1425–1429. https://doi.org/10.1211/0022357001777432

L. D. Kapoor, "Handbook of Ayurvedic Medicinal Plants," CRC Press, Boca Raton, 1990. - References - Scientific Research Publishing. (n.d.).

Le Bars, P. L., Kieser, M., & Itil, K. Z. (2000). A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761® in dementia. *Dementia and Geriatric Cognitive Disorders*, *11*(4), 230–237. https://doi.org/10.1159/000017242

Lee, M.-M., Hseih, M.-T., Kuo, J.-S., Yeh, F.-T., & Huang, H.-M. (1998). Magnolol protects cortical neuronal cells from chemical hypoxia in rats. *NeuroReport*, *9*(15), 3451–3456. https://doi.org/10.1097/00001756-199810260-00021

Lesage, S., & Brice, A. (2009). Parkinson's disease: From monogenic forms to genetic susceptibility factors. *Human Molecular Genetics*, *18*(R1), 48–59. https://doi.org/10.1093/hmg/ddp012

Levy-lahad, E., Sparkes, R. S., Rimoin, D. L., Wasco, W., Poorkaj, P., Romano, D. M., … Tanzi, R. E. (1995). Candidate Gene for the Chromosome 1 Familial Alzheimer's Disease Locus. *Science*, *269*, 973.

Lin, M. T., & Beal, M. F. (2006, October). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature*. Nature. https://doi.org/10.1038/nature05292

Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P., & Zuo, L. (2017). Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications.

Oxidative Medicine and Cellular Longevity, *2017*. https://doi.org/10.1155/2017/2525967

Löffler, T., Lee, S. K., Nöldner, M., Chatterjee, S. S., Hoyer, S., & Schliebs, R. (2001). Effect of Ginkgo biloba extract (EGb761) on glucose metabolism-related markers in streptozotocin-damaged rat brain. *Journal of Neural Transmission*, *108*(12), 1457–1474. https://doi.org/10.1007/s007020100020

Lui, A. J., & Byl, N. N. (2009). A systematic review of the effect of moderate intensity exercise on function and disease progression in amyotrophic lateral sclerosis. *Journal of Neurologic Physical Therapy*, *33*(2), 68–87. https://doi.org/10.1097/NPT.0b013e31819912d0

Luo, L., Nong Wang, J., Kong, L. D., Jiang, Q. G., & Tan, R. X. (2000). Antidepressant effects of Banxia Houpu decoction, a traditional Chinese medicinal empirical formula. *Journal of Ethnopharmacology*, *73*(1–2), 277–281. https://doi.org/10.1016/S0378-8741(00)00242-7

Madabhushi, R., Pan, L., & Tsai, L. H. (2014, July). DNA damage and its links to neurodegeneration. *Neuron*. Cell Press. https://doi.org/10.1016/j.neuron.2014.06.034

Malhotra, C. L., Mehta, V. L., Das, P. K., & Dhalla, N. S. (1965). Studies on Withania-ashwagandha, Kaul. V. The effect of total alkaloids (ashwagandholine) on the central nervous system. *Indian Journal of Physiology and Pharmacology*, *9*(3), 127–136.

Mandal, B. A. (n.d.). Neurodegeneration - What is Neurodegeneration?, 1. https://doi.org/10.1111/j.1460

Manyam, B. V. (1999). Dementia in Ayurveda. *Journal of Alternative and Complementary Medicine*, *5*(1), 81–88. https://doi.org/10.1089/acm.1999.5.81

Marcocci, L., Packer, L., Droy-Lefaix, M. T., Sekaki, A., & Gardès-Albert, M. (1994). Antioxidant action of Ginkgo biloba extract EGb 761. *Methods in Enzymology*, *234*(C), 462–475. https://doi.org/10.1016/0076-6879(94)34117-6

Marsh, J. L., Lukacsovich, T., & Thompson, L. M. (2009, March). Animal models of polyglutamine diseases and therapeutic approaches. *Journal of Biological Chemistry*. J Biol Chem. https://doi.org/10.1074/jbc.R800065200

Martin, S., Al Khleifat, A., & Al-Chalabi, A. (2017). What causes amyotrophic lateral sclerosis? *F1000Research*. Faculty of 1000 Ltd.

https://doi.org/10.12688/f1000research.10476.1

Mayeux, R. (2003). Epidemiology of neurodegeneration. *Annual Review of Neuroscience*, *26*, 81–104. https://doi.org/10.1146/annurev.neuro.26.043002.094919

McGee, D. J., Lu, X. H., & Disbrow, E. A. (2018). Stomaching the possibility of a pathogenic role for helicobacter pylori in Parkinson's disease. *Journal of Parkinson's Disease*, *8*(3), 367–374. https://doi.org/10.3233/JPD-181327

Mcgill-carter, T. (2020). Market analysis alzheimers disease 2020. *Journal of Psychiatry*, *22*(6), 21–22.

Medicinal Plants of the World, Volume 2 | NHBS Academic & Professional Books. (n.d.).

Mehta, A., Binkley, P., Gandhi, S., & Ticku, M. (1991). Pharmacological effects of Withania somnifera root extract on GABAA receptor complex. *Undefined*.

Misane, I., & Ögren, S. O. (2001). Effects of Hypericum perforatum (St. John's wort) on passive avoidance in the rat: Evaluation of potential neurochemical mechanisms underlying its antidepressant activity. In *Pharmacopsychiatry* (Vol. 34). Georg Thieme Verlag. https://doi.org/10.1055/s-2001-15449

Mishra, L. C., Singh, B. B., & Dagenais, S. (2000, August). Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): A review. *Alternative Medicine Review*.

Miyazawa, M., Watanabe, H., & Kameoka, H. (1997). Inhibition of Acetylcholinesterase Activity by Monoterpenoids with a *p* -Menthane Skeleton. *Journal of Agricultural and Food Chemistry*, *45*(3), 677–679. https://doi.org/10.1021/jf960398b

Mizuno, N., Varkey, J., Kegulian, N. C., Hegde, B. G., Cheng, N., Langen, R., & Steven, A. C. (2012). Remodeling of lipid vesicles into cylindrical micelles by α-synuclein in an extended α-helical conformation. *Journal of Biological Chemistry*, *287*(35), 29301–29311. https://doi.org/10.1074/jbc.M112.365817

Monti, N., Cavallaro, R. A., Stoccoro, A., Nicolia, V., Scarpa, S., Kovacs, G. G., … Fuso, A. (2020). CpG and non-CpG Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated with gene expression in human and murine brain. *Epigenetics*, *15*(8), 781–799. https://doi.org/10.1080/15592294.2020.1722917

Montoya, A., Price, B. H., Menear, M., & Lepage, M. (2006, January). Brain imaging and cognitive dysfunctions in Huntington's disease. *Journal of Psychiatry and Neuroscience*. Canadian Medical Association.

Moritz, D. J., Fox, P. J., Luscombe, P. A., & Kraemer, H. C. (1997). Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. *Archives of Neurology*, *54*(7), 878–885. https://doi.org/10.1001/archneur.1997.00550190066016

Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., & Przedborski, S. (2007). Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. *Nature Neuroscience*, *10*(5), 615–622. https://doi.org/10.1038/nn1876

Nalini, K., Aroor, A. R., Karanth, K. S., & Rao, A. (1992). Effect of Centella asiatica fresh leaf aqueous extract on learning and memory and biogenic amine turnover in albino rats. *Fitoterapia*, *63*(3), 232–237.

Newhouse, P. A., & Kelton, M. (2000). Nicotinic systems in central nervous systems disease: Degenerative disorders and beyond. In *Pharmaceutica Acta Helvetiae* (Vol. 74, pp. 91–101). Pharm Acta Helv. https://doi.org/10.1016/S0031-6865(99)00047-3

Nguyen, H. H. P., & Cenci, M. A. (Eds.). (2015). *Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease* (Vol. 22). Berlin, Heidelberg: Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-662-46344-4

Noyce, A. J., Bestwick, J. P., Silveira-Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012). Meta-analysis of early nonmotor features and risk factors for Parkinson disease. *Annals of Neurology*, *72*(6), 893–901. https://doi.org/10.1002/ana.23687

Ohnishi, S., & Takano, K. (2004). Amyloid fibrils from the viewpoint of protein folding. *Cellular and Molecular Life Sciences*, *61*(5), 511–524. https://doi.org/10.1007/s00018-003-3264-8

Orr, H. T. (2009, March). Unstable nucleotide repeat mini review series: A molecular biography of unstable repeat disorders. *Journal of Biological Chemistry*. J Biol Chem. https://doi.org/10.1074/jbc.R800067200

Öztürk, Y., Aydin, S., Beis, R., Başer, K. H. C., & Berberoğlu, H. (1996). Effects of Hypericum perforatum L and Hypericum calycinum L extracts on the central nervous system in mice. *Phytomedicine*, *3*(2), 139–146. https://doi.org/10.1016/S0944-7113(96)80027-4

Parkinson's Disease Mechanism Discovered | HHMI.org. (n.d.).

Pastorino, L., Ikin, A. F., Lamprianou, S., Vacaresse, N., Revelli, J. P., Platt, K., … Buxbaum, J. D. (2004). BACE (β-secretase) modulates the processing of APLP2 in vivo. *Molecular and Cellular Neuroscience*, *25*(4), 642–649. https://doi.org/10.1016/j.mcn.2003.12.013

Perfumi, M., Mattioli, L., Forti, L., Massi, M., & Ciccocioppo, R. (2005). Effect of Hypericum perforatum CO2 extract on the motivational properties of ethanol in alcohol-preferring rats. *Alcohol and Alcoholism*, *40*(4), 291–296. https://doi.org/10.1093/alcalc/agh133

Perry, E., & Howes, M. J. R. (2011, December). Medicinal plants and dementia therapy: Herbal hopes for brain aging? *CNS Neuroscience and Therapeutics*. Wiley-Blackwell. https://doi.org/10.1111/j.1755-5949.2010.00202.x

Perry, E. K., Pickering, A. T., Wang, W. W., Houghton, P., & Perry, N. S. L. (1998). Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. *Journal of Alternative and Complementary Medicine*, *4*(4), 419–428. https://doi.org/10.1089/acm.1998.4.419

Perry, N. S. L., Houghton, P. J., Sampson, J., Theobald, A. E., Hart, S., Lis-Balchin, M., … Perry, E. K. (2001). In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease . *Journal of Pharmacy and Pharmacology*, *53*(10), 1347–1356. https://doi.org/10.1211/0022357011777846

PERRY, N. S. L., HOUGHTON, P. J., THEOBALD, A., JENNER, P., & PERRY, E. K. (2000). In-vitro Inhibition of Human Erythrocyte Acetylcholinesterase by Salvia lavandulaefolia Essential Oil and Constituent Terpenes . *Journal of Pharmacy and Pharmacology*, *52*(7), 895–902. https://doi.org/10.1211/0022357001774598

Petkov, V. D., Kehayov, R., Belcheva, S., Konstantinova, E., Petkov, V. V., Getova, D., & Markovska, V. (1993). Memory effects of standardized extracts of Panax ginseng

(G115), Ginkgo biloba (GK501) and their combination Gincosan® (PHL-00701). *Planta Medica*, *59*(2), 106–114. https://doi.org/10.1055/s-2006-959623

Presenilin I Protein - Alzheimer's Disease:the influence of presenilin I. (n.d.).

Priller, C., Bauer, T., Mitteregger, G., Krebs, B., Kretzschmar, H. A., & Herms, J. (2006). Synapse formation and function is modulated by the amyloid precursor protein. *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience*, *26*(27), 7212–7221. https://doi.org/10.1523/JNEUROSCI.1450-06.2006

prince, martin. (2015). World Alzheimer Report.

Przedborski, S., Vila, M., & Jackson-Lewis, V. (2003). Neurodegeneration: What is it and where are we? *Journal of Clinical Investigation*, *111*(1), 3–10. https://doi.org/10.1172/JCI200317522

Quadri, M., Mandemakers, W., Grochowska, M. M., Masius, R., Geut, H., Fabrizio, E., … Bonifati, V. (2018). LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. *The Lancet Neurology*, *17*(7), 597–608. https://doi.org/10.1016/S1474-4422(18)30179-0

Querfurth, H. W., & Laferla, F. M. (2010). Alzheimer's Disease, 329–344.

Raaphorst, J., Beeldman, E., De Visser, M., De Haan, R. J., & Schmand, B. (2012, October). A systematic review of behavioural changes in motor neuron disease. *Amyotrophic Lateral Sclerosis*. Amyotroph Lateral Scler. https://doi.org/10.3109/17482968.2012.656652

Rahman, M. R., Tajmim, A., Ali, M., & Sharif, M. (2017). Overview and Current Status of Alzheimer's Disease in Bangladesh. *Journal of Alzheimer's Disease Reports*, *1*(1), 27–42. https://doi.org/10.3233/adr-170012

Review, I. (2008). Immune activation and inflammation in HIV-1 infection :, (September), 231–241. https://doi.org/10.1002/path

Ross, J. M., Stewart, J. B., Hagström, E., Brené, S., Mourier, A., Coppotelli, G., … Larsson, N. G. (2013). Germline mitochondrial DNA mutations aggravate ageing and can impair brain development. *Nature*, *501*(7467), 412–415. https://doi.org/10.1038/nature12474

Rubinsztein, D. C. (2006). The roles of intracellular protein-degradation pathways in

neurodegeneration. *Nature*, *443*(7113), 780–786. https://doi.org/10.1038/nature05291

Ryan, M. F., & Byrne, O. (1988). Plant-insect coevolution and inhibition of acetylcholinesterase. *Journal of Chemical Ecology*, *14*(10), 1965–1975. https://doi.org/10.1007/BF01013489

Sahakian, B., Jones, G., Levy, R., Gray, J., & Warburton, D. (1989). The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. *British Journal of Psychiatry*, *154*(JUN.), 797–800. https://doi.org/10.1192/bjp.154.6.797

Sakina, M. R., & Dandiya, P. C. (1990). A psycho-neuropharmacological profile of Centella asiatica extract. *Undefined*.

Schenk, D., Basi, G. S., & Pangalos, M. N. (2012). Treatment strategies targeting amyloid β-protein. *Cold Spring Harbor Perspectives in Medicine*, *2*(9). https://doi.org/10.1101/cshperspect.a006387

Schneider, L. S., Farlow, M. R., & Pogoda, J. M. (1997). Potential role for estrogen replacement in the treatment of Alzheimer's dementia. In *American Journal of Medicine* (Vol. 103, pp. 46S-50S). Elsevier Inc. https://doi.org/10.1016/S0002-9343(97)00257-X

Shaheen, H. M., Ali, B. H., Alqarawi, A. A., & Bashir, A. K. (2000). The ameliorating effects of the cognitive-enhancing Chinese herbs on scopolamine- induced amnesia in rats. *Phytotherapy Research*, *14*(5), 375–377. https://doi.org/10.1002/1099-1573(200008)14:5<375::AID-PTR593>3.0.CO;2-5

Shampo, M. A., Kyle, R. A., & Steensma, D. P. (2013). Alois Alzheimer–Alzheimer Disease. *Mayo Clinic Proceedings*, *88*(12), e155. https://doi.org/10.1016/j.mayocp.2013.01.031

Singh, H. K., & Dhawan, B. N. (1982). Effect of Bacopa monniera Linn. (Brāhmi) extract on avoidance responses in rat. *Journal of Ethnopharmacology*, *5*(2), 205–214. https://doi.org/10.1016/0378-8741(82)90044-7

Soodi, M., Naghdi, N., Hajimehdipoor, H., Choopani, S., & Sahraei, E. (2014). Memory-improving activity of Melissa officinalis extract in naïve and scopolamine-treated Rats. *Research in Pharmaceutical Sciences*, *9*(2), 107–114.

Squires, R. F., Ai, J., Witt, M. R., Kahnberg, P., Saederup, E., Sterner, O., & Nielsen, M. (1999). Honokiol and magnolol increase the number of [3H]muscimol binding sites

three-fold in rat forebrain membranes in vitro using a filtration assay, by allosterically increasing the affinities of low-affinity sites. *Neurochemical Research*, *24*(12), 1593–1602. https://doi.org/10.1023/A:1021116502548

Stern, Y., Gurland, B., Tatemichi, T. K., Tang, M. X., Wilder, D., & Mayeux, R. (1994). Influence of Education and Occupation on the Incidence of Alzheimer's Disease. *JAMA: The Journal of the American Medical Association*, *271*(13), 1004–1010. https://doi.org/10.1001/jama.1994.03510370056032

Stoker, T. B., Torsney, K. M., & Barker, R. A. (2018). Parkinson ' s Disease, 45–64.

Sudhir, S., Budhiraja, R., Miglani, G., Arora, B., Gupta, L., & Garg, K. (1986). Pharmacological Studies on Leaves of *Withania somnifera*. *Planta Medica*, *52*(01), 61–63. https://doi.org/10.1055/s-2007-969072

Sugaya, K., Uz, T., Kumar, V., & Manev, H. (2000). New anti-inflammatory treatment strategy in Alzheimer's disease. *Japanese Journal of Pharmacology*. Jpn J Pharmacol. https://doi.org/10.1254/jjp.82.85

Sweetlove, M. (2012). Phase III CONCERT Trial of Latrepirdine. *Pharmaceutical Medicine*, *26*(2), 113–115. https://doi.org/10.1007/bf03256900

Swerdlow, R. H. (2007). *Pathogenesis of Alzheimer's disease*. *Clinical Interventions in Aging* (Vol. 2).

Szyszkowicz, M., Kousha, T., Kingsbury, M., & Colman, I. (2016). Air Pollution and Emergency Department Visits for Depression: A Multicity Case-Crossover Study. *Environmental Health Insights*, *10*, 155. https://doi.org/10.4137/EHI.S40493

Taylor, J. D., & Matthews, S. J. (2015). New insight into the molecular control of bacterial functional amyloids. *Frontiers in Cellular and Infection Microbiology*, *5*(APR), 33. https://doi.org/10.3389/fcimb.2015.00033

Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002). Toxic proteins in neurodegenerative disease. *Science*, *296*(5575), 1991–1995. https://doi.org/10.1126/science.1067122

The Behavioral Symptoms of Huntington's Disease – HOPES Huntington's Disease Information. (n.d.).

Thompson, L. M. (2008, April). Neurodegeneration: A question of balance. *Nature*. Nature

Publishing Group. https://doi.org/10.1038/452707a

Tildesley, N. T. J., Kennedy, D. O., Perry, E. K., Ballard, C. G., Wesnes, K. A., & Scholey, A. B. (2005). Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. *Physiology and Behavior*, *83*(5), 699–709. https://doi.org/10.1016/j.physbeh.2004.09.010

Tiraboschi, P., Hansen, L. A., Thal, L. J., & Corey-Bloom, J. (2004). The importance of neuritic plaques and tangles to the development and evolution of AD. *Neurology*, *62*(11), 1984–1989. https://doi.org/10.1212/01.WNL.0000129697.01779.0A

Tohda, C., Kuboyama, T., & Komatsu, K. (2000). Dendrite extension by methanol extract of Ashwagandha (roots of Withania somnifera) in SK-N-SH cells. *NeuroReport*, *11*(9), 1981–1985. https://doi.org/10.1097/00001756-200006260-00035

Topic, B., Tani, E., Tsiakitzis, K., Kourounakis, P. N., Dere, E., Hasenöhrl, R. U., … Huston, J. P. (2002). Enhanced maze performance and reduced oxidative stress by combined extracts of zingiber officinale and ginkgo biloba in the aged rat. *Neurobiology of Aging*, *23*(1), 135–143. https://doi.org/10.1016/S0197-4580(01)00241-X

Torrent, M., Pulido, D., Victò Ria Nogué, M., Boix, E., & Seifert, S. (2012). Exploring New Biological Functions of Amyloids: Bacteria Cell Agglutination Mediated by Host Protein Aggregation. https://doi.org/10.1371/journal.ppat.1003005

Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., … Larsson, N. G. (2004). Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature*, *429*(6990), 417–423. https://doi.org/10.1038/nature02517

Trojanowski, J. Q., & Lee, V. M.-Y. (2000). " Fatal Attractions " of Proteins Underlying Alzheimer ' s Disease and Other. *Annals New York Academy of Sciences*, *924*, 62–67.

Tshikantwa, T. S., Ullah, M. W., He, F., & Yang, G. (2018, June). Current trends and potential applications of microbial interactions for human welfare. *Frontiers in Microbiology*. Frontiers Media S.A. https://doi.org/10.3389/fmicb.2018.01156

Tsuji, S. (2010). Genetics of neurodegenerative diseases: Insights from high-throughput resequencing. *Human Molecular Genetics*, *19*(R1), 65–70.

https://doi.org/10.1093/hmg/ddq162

Turner, P. R., O'Connor, K., Tate, W. P., & Abraham, W. C. (2003). *Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory*. *Progress in Neurobiology* (Vol. 70). https://doi.org/10.1016/S0301-0082(03)00089-3

van der Burg, J. M., Björkqvist, M., & Brundin, P. (2009, August). Beyond the brain: widespread pathology in Huntington's disease. *The Lancet Neurology*. Lancet Publishing Group. https://doi.org/10.1016/S1474-4422(09)70178-4

Van Duijn, E., Kingma, E. M., & Van Der Mast, R. C. (2007). Psychopathology in verified Huntington's disease gene carriers. *Journal of Neuropsychiatry and Clinical Neurosciences*, *19*(4), 441–448. https://doi.org/10.1176/jnp.2007.19.4.441

Varkey, J., Isas, J. M., Mizuno, N., Jensen, M. B., Bhatia, V. K., Jao, C. C., … Langen, R. (2010). Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. *Journal of Biological Chemistry*, *285*(42), 32486–32493. https://doi.org/10.1074/jbc.M110.139576

Varkey, J., Mizuno, N., Hegde, B. G., Cheng, N., Steven, A. C., & Langen, R. (2013). α-synuclein oligomers with broken helical conformation form lipoprotein nanoparticles. *Journal of Biological Chemistry*, *288*(24), 17620–17630. https://doi.org/10.1074/jbc.M113.476697

Vila, M., & Przedborski, S. (2003). Targeting programmed cell death in neurodegenerative diseases. *Nature Reviews Neuroscience*, *4*(5), 1–11. https://doi.org/10.1038/nrn1100

Vineet, B., Singh, K., Mundkinajeddu, D., Agarwal, A., Nguyen, J., Sudberg, S., & Gafner, S. (2019). Adulteration of Ashwagandha. *Botanical Adulterants Bulletin*, (January), 1–7.

Vohora, D., Pal, S. N., & Pillai, K. K. (2000). Protection from phenytoin-induced cognitive deficit by Bacopa monniera, a reputed Indian nootropic plant. *Journal of Ethnopharmacology*, *71*(3), 383–390. https://doi.org/10.1016/S0378-8741(99)00213-5

Vonsattel, J. P. G., & DiFiglia, M. (1998). Huntington disease. *Journal of Neuropathology and Experimental Neurology*, *57*(5), 369–384. https://doi.org/10.1097/00005072-199805000-00001

Walker, F. O. (2007). Huntington's disease. In *Lancet* (Vol. 369, pp. 218–228). Elsevier. https://doi.org/10.1016/S0140-6736(07)60111-1

Wang, H., Dharmalingam, P., Vasquez, V., Mitra, J., Boldogh, I., Rao, K. S., … Hegde, M. L. (2017, January). Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target? *Mechanisms of Ageing and Development*. Elsevier Ireland Ltd. https://doi.org/10.1016/j.mad.2016.09.005

WANG, J. -P, HO, T. -F, CHANG, L. -C, & CHEN, C. -C. (1995). 857-860Anti-inflammatory Effect of Magnolol, Isolated from Magnolia officinalis, on A23187-induced Pleurisy in Mice. *Journal of Pharmacy and Pharmacology*, *47*(10), 857–860. https://doi.org/10.1111/j.2042-7158.1995.tb05754.x

Wang, M., Kikuzaki, H., Zhu, N., Sang, S., Nakatani, N., & Ho, C. T. (2000). Isolation and structural elucidation of two new glycosides from sage (Salvia officinalis L.). *Journal of Agricultural and Food Chemistry*, *48*(2), 235–238. https://doi.org/10.1021/jf990761p

Wang, M., Shao, Y., Li, J., Zhu, N., Rangarajan, M., LaVoie, E. J., & Ho, C. T. (1999). Antioxidative phenolic glycosides from sage (Salvia officinalis). *Journal of Natural Products*, *62*(3), 454–456. https://doi.org/10.1021/np980436g

Wenk, G. L. (2006). Neuropathologic changes in Alzheimer's disease: Potential targets for treatment. *Journal of Clinical Psychiatry*, *67*(SUPPL. 3), 3–7.

Whiskey, E., Werneke, U., & Taylor, D. (2001). A systematic review and meta-analysis of Hypericum perforatum in depression: A comprehensive clinical review. *International Clinical Psychopharmacology*. Lippincott Williams and Wilkins. https://doi.org/10.1097/00004850-200109000-00001

WHO | Dementia cases set to triple by 2050 but still largely ignored. (2013). *WHO*.

Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., Prina, A. M., Winblad, B., … Prince, M. (2017). The worldwide costs of dementia 2015 and comparisons with 2010. *Alzheimer's and Dementia*, *13*(1), 1–7. https://doi.org/10.1016/j.jalz.2016.07.150

Zagzoule, M., & Marc-Vergnes, J. P. (1986). A global mathematical model of the cerebral circulation in man. *Journal of Biomechanics*, *19*(12), 1015–1022. https://doi.org/10.1016/0021-9290(86)90118-1

Zheng, W., & Wang, S. Y. (2001). Antioxidant activity and phenolic compounds in selected herbs. *Journal of Agricultural and Food Chemistry*, *49*(11), 5165–5170.

https://doi.org/10.1021/jf010697n

Zoghbi, H. Y., & Orr, H. T. (2009, March). Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, Spinocerebellar ataxia type 1. *Journal of Biological Chemistry*. J Biol Chem. https://doi.org/10.1074/jbc.R800041200